var title_f19_56_20352="Chromagar for Candida isolation";
var content_f19_56_20352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chromagar medium for the identification of Candida species",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chromogenic agar culture medium is commercially available which permits presumptive identification of C. albicans (green colonies), C. tropicalis (bluish-purple colonies), C. krusei (filamentous, large pink colonies) and C. glabrata (pink yeast colonies).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from J Microbiol 1994; 32:1923.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20352=[""].join("\n");
var outline_f19_56_20352=null;
var title_f19_56_20353="Pemphigoid gestationis umb";
var content_f19_56_20353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigold gestationis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Periumbilical erythematous papules, vesicles, erosions, and crusts are present in this patient with pemphigold gestations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20353=[""].join("\n");
var outline_f19_56_20353=null;
var title_f19_56_20354="Brachial artery tethering";
var content_f19_56_20354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Brachial artery tethering in a supracondylar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The branchial artery may be tethered to the sharp edge of the proximal supracondylar fracture fragment by the supratrochlear branch of the anterior ulnar recurrent artery, thereby increasing the risk of brachial artery injury during movement of the injured arm or fracture manipulation",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20354=[""].join("\n");
var outline_f19_56_20354=null;
var title_f19_56_20355="Modified Martius fat pad graft3";
var content_f19_56_20355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Martius fat pad graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The graft is tunneled subcutaneously beneath the vaginal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20355=[""].join("\n");
var outline_f19_56_20355=null;
var title_f19_56_20356="Urothelial carcinoma";
var content_f19_56_20356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20356=[""].join("\n");
var outline_f19_56_20356=null;
var title_f19_56_20357="Fascia iliaca block";
var content_f19_56_20357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Fascia iliaca block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 639px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is placed in a supine position. A line is drawn between the anterior superior iliac spine (ASIS) and pubic tubercle and divided into thirds. At the border between the lateral and medial thirds, a perpendicular line 2 cm in length is drawn caudally. A blunt needle is inserted, and directed cephalad. Local anesthetic is injected when the operator appreciates two distinct \"pops\", first through the fascia lata and then through fascia iliaca. Utrasound is commonly used to aid with the approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20357=[""].join("\n");
var outline_f19_56_20357=null;
var title_f19_56_20358="Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia";
var content_f19_56_20358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Claire Dearden, MD, BSc, FRCP, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20358/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/56/20358/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell prolymphocytic leukemia (B-PLL) is a very rare B cell neoplasm comprised of so-called prolymphocytes, typically with involvement of the peripheral blood, bone marrow, and spleen. The name \"prolymphocyte\" is actually a misnomer, as the tumor cells in this disease are mature activated B cells. By definition, these prolymphocytes comprise greater than 55 percent of the cells in the blood and bone marrow.",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, pathology, and diagnosis of B-PLL are discussed here. The treatment of B-PLL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'B cell PLL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-PLL is an extremely rare disease, comprising far less than 1 percent of B cell leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/1\">",
"     1",
"    </a>",
"    ]. Since the diagnosis was changed to exclude cases of mantle cell lymphoma, atypical chronic lymphocytic leukemia (CLL), and",
"    <span class=\"nowrap\">",
"     CLL/PLL",
"    </span>",
"    (defined as between 15 and 55 percent prolymphocytes), B-PLL has become increasingly rare.",
"   </p>",
"   <p>",
"    B-PLL mainly affects the elderly with a mean age at presentation of between 65 and 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/2\">",
"     2",
"    </a>",
"    ]. Men and women appear to be equally affected [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/1\">",
"     1",
"    </a>",
"    ]. The vast majority of patients are Caucasian.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically present with a rapidly rising white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL",
"    </span>",
"    and massive splenomegaly; anemia and thrombocytopenia are present in approximately 65 and 35 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Systemic B symptoms (ie, fevers, night sweats, weight loss) are common. If present, peripheral lymphadenopathy is not prominent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Systemic complaints (B symptoms)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Peripheral blood and bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, more than 55 percent of the circulating cells in the peripheral blood are prolymphocytes; more typically, the percentage of prolymphocytes is greater than 90 percent. Peripheral blood prolymphocytes are medium-sized cells (approximately twice the size of a small lymphocyte), with moderately condensed chromatin and a single, prominent vesicular nucleolus (",
"    <a class=\"graphic graphic_picture graphicRef85966 \" href=\"UTD.htm?4/32/4615\">",
"     picture 1",
"    </a>",
"    ). The nucleus is typically round or oval, and the cytoplasm is usually moderately abundant and slightly basophilic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells (",
"    <a class=\"graphic graphic_picture graphicRef70577 \" href=\"UTD.htm?42/12/43207\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-PLL is only rarely diagnosed in tissues other than the blood and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spleen shows extensive white and red pulp infiltration by prolymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/2,7-9\">",
"       2,7-9",
"      </a>",
"      ] morphologically similar to those seen in the blood and bone marrow (",
"      <a class=\"graphic graphic_picture graphicRef85967 \" href=\"UTD.htm?40/47/41719\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Involved lymph nodes may show vague nodularity, but the proliferation centers (pseudofollicles) seen in CLL are absent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/2,7-9\">",
"       2,7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-PLL is a tumor of monoclonal B cells that typically express bright surface IgM",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    IgD, bright surface Ig kappa or lambda light chain, bright CD20, and CD19, CD22, CD79a, and FMC7. This is in contrast to chronic lymphocytic leukemia (CLL) which generally has dim expression of surface Ig and CD20. ZAP-70 and CD38 are expressed in about 50 percent of cases, while CD5 and CD23 are expressed in about one-third of cases.",
"   </p>",
"   <p>",
"    CD38 and ZAP-70 do not have prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/10\">",
"     10",
"    </a>",
"    ]. Helping to distinguish B-PLL from other lymphoproliferative disorders is the absence of expression of CD11c, CD103, CD10, CD25, and cyclin D1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic lesions underlying B-PLL are largely unknown. Deletions of 17p (the chromosomal arm that carries the p53 gene) and p53 mutations are found in more than half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/11\">",
"     11",
"    </a>",
"    ]. Deletions of 13q14, the site of the retinoblastoma gene, occur in about 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Prior to the current World Health Organization (WHO) classification system, translocations involving 14q32 were reported in two-thirds of patients with B-PLL, the most common being the t(11;14)(q13;q32) involving the cyclin D1 gene. However, patients with this translocation are now considered to have a leukemic variant of mantle cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/14\">",
"     14",
"    </a>",
"    ]. As such, it is important to exclude this translocation, either by cytogenetic testing or by immunohistochemical staining for cyclin D1, in cases of suspected B-PLL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunoglobulin genes are clonally rearranged, and in approximately half of cases demonstrate somatic hypermutation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/4\">",
"     4",
"    </a>",
"    ]. Although not used in routine practice, the gene expression profile of B-PLL is different from that of CLL and displays over-expression of c-MYC and AKT, and downregulation of p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of B-PLL is usually made by bone marrow biopsy and aspirate with flow cytometry and genetic studies. When the white blood cell count is elevated and an evaluation of the peripheral blood and bone marrow is consistent with B-PLL, lymph node biopsy rarely adds additional information and is not necessary. Splenectomy can be diagnostic in patients with an unclear presentation and a massively enlarged spleen.",
"   </p>",
"   <p>",
"    By definition, prolymphocytes must exceed 55 percent of lymphoid cells in the peripheral blood. These cells can be confirmed by flow cytometry demonstrating a characteristic immunophenotype with light chain restriction, bright surface immunoglobulin, and the expression of B cell antigens (eg, CD20, CD22, FMC7, CD79a). CD5 and CD23 expression is usually weak or absent. CD11c, CD103, CD10, and CD25 are not expressed. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Immunophenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Tumors demonstrating t(11;14)(q13;q32) must be excluded by either conventional cytogenetics or fluorescence in situ hybridization (FISH). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Genetic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of B-PLL includes other chronic lymphoid neoplasms with a leukemic presentation (",
"    <a class=\"graphic graphic_table graphicRef54944 \" href=\"UTD.htm?30/55/31612\">",
"     table 1",
"    </a>",
"    ). They are described in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     T cell prolymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell prolymphocytic leukemia (T-PLL) has a similar clinical presentation and morphologic appearance to B-PLL however differs in its immunophenotype. Unlike B-PLL, T-PLL expresses one or more T cell antigens (CD2, CD3, CD7, CD53). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both B-PLL and chronic lymphocytic leukemia (CLL) can present with lymphocytosis, splenomegaly, and circulating prolymphocytes in the blood, but in CLL prolymphocytes comprise less than 55 percent of the cells, whereas in most cases of B-PLL greater than 90 percent of the cells are pro-lymphocytes. Compared with typical CLL cells, prolymphocytes are larger cells with somewhat immature-appearing nuclear chromatin, a prominent nucleolus, and a moderate amount of cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef85966 \" href=\"UTD.htm?4/32/4615\">",
"     picture 1",
"    </a>",
"    ). While prolymphocytes are seen in variable numbers in CLL, they typically comprise over 90 percent of the neoplastic cells in B-PLL and usually comprise fewer than 10 percent of the circulating cells in CLL. In addition, in two-thirds of cases of B-PLL the prolymphocytes are CD5 negative, whereas as a rule the prolymphocytes of CLL are CD5 positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with peripheral blood prolymphocyte counts between 10 and 55 percent have been designated as having chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/prolymphocytic",
"    </span>",
"    leukemia in the past, but this entity has been eliminated in the latest WHO classification of lymphoid neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/4\">",
"     4",
"    </a>",
"    ]. Rarely, cases of CLL can undergo prolymphocytoid transformation. In such cases, the peripheral blood will contain a mixture of small mature CLL cells and prolymphocytes. The prolymphocytes in such cases usually have an immunophenotype similar to that seen with typical CLL, although sometimes with higher levels of surface Ig. In contrast, circulating cells in de novo B-PLL are monomorphic prolymphocytes with an immunophenotype characteristic of B-PLL as described above. In addition, histologic findings on bone marrow biopsy in cases of CLL with prolymphocytoid transformation are consistent with those found in CLL (eg, proliferation centers). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Immunophenotype'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H23#H23\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Prolymphocytoid transformation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL) can have a leukemic phase that mimics B-PLL. As in a subset of B-PLLs, MCL cells co-express CD5 and CD20. However, the neoplastic cells of MCL express cyclin D1, which is dysregulated by a (11;14) translocation involving the cyclin D1 gene. SOX11 expression is usually present in the rare cases of MCL that do not express cyclin D1. In contrast, the malignant cells in PLL are negative for cyclin D1 and do not demonstrate t(11;14). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;On rare occasions, patients with follicular lymphoma can have a leukemic phase, but this usually does not present a diagnostic dilemma, as the circulating tumor cells in typical cases are centrocytes with highly irregular or cleaved nuclear contours that by flow cytometry express CD10. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lymphoplasmacytic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoplasmacytic lymphoma (LPL), a tumor that is commonly associated with Waldenstrom macroglobulinemia, occasionally involves the peripheral blood. However, the circulating malignant cells of LPL often have a plasmacytoid appearance and are usually few in number, whereas B-PLL is usually associated with WBCs of over 100,000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    Moreover, B-PLL is never associated with a significant level of paraproteinemia, whereas this is typical of patients with LPL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variant of hairy cell leukemia (HCL-variant) that exhibits morphologic features intermediate between hairy cells and prolymphocytes. Such cases may also have extreme leukocytosis and expression of the interleukin-2 receptor beta chain, but not the alpha chain (CD25). Unlike B-PLL, most cases of HCL-variant express some combination of CD11c, CD103, CD123, cyclin D1, and annexin A1, none of which are typically expressed on B-PLL cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16450299\">",
"    <span class=\"h2\">",
"     Splenic marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both splenic marginal zone lymphoma (MZL) and B-PLL can present with splenomegaly and peripheral blood lymphocytosis. When compared with splenic MZL, B-PLL is more likely to present with clinically aggressive disease, B symptoms, and extreme leukocytosis",
"    <span class=\"nowrap\">",
"     (&gt;100,000/microL).",
"    </span>",
"    While the circulating lymphocytes in B-PLL usually have a regular, smooth cytoplasmic outline, splenic MZL cells usually have short polar villi, although this may be masked by poor slide preparation. Both B-PLL and splenic MZL express CD20 and bright surface Ig. Neither typically expresses CD5. Expression of CD22 is usually strong in B-PLL and variable in MZL. Both MZL and B-PLL involve both the splenic white pulp and red pulp, but in MZL marginal zones are usually prominent due to expansion by cells with abundant pale cytoplasm, and plasmacytic differentiation may also be observed, features that are absent in B-PLL. Bone marrow morphology in MZL may take the form of reactive-appearing follicles surrounded by marginal zone B cells, features that are not seen in B-PLL. In difficult cases, pathologic evaluation of the bone marrow, spleen, and hilar lymph nodes may be used in concert to determine the most likely diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival of patients with B-PLL is usually three to five years despite therapy. It has been difficult to determine prognostic markers for patients with B-PLL because it is such a rare tumor and because previous reports contained not only patients with B-PLL but also patients with T cell prolymphocytic leukemia and mantle cell lymphoma.",
"   </p>",
"   <p>",
"    Among patients with B-PLL, prognostic features that suggest a poor outcome include anemia, thrombocytopenia, advanced age, and the presence of p53 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. Unlike in patients with chronic lymphocytic leukemia, neither ZAP-70 expression, immunoglobulin heavy chain gene mutations, CD38 expression, nor 17p deletion appear to act as prognostic markers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20358/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B cell prolymphocytic leukemia (B-PLL) is a rare B cell neoplasm comprised of prolymphocytes, typically with involvement of the peripheral blood, bone marrow, and spleen. It is most common in elderly Caucasians. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with a rapidly rising white blood count",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      and massive splenomegaly with or without B symptoms (ie, fevers, night sweats, weight loss). If present, peripheral lymphadenopathy is not prominent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually made by bone marrow biopsy and aspirate with flow cytometry and genetic studies. By definition, prolymphocytes must exceed 55 percent of lymphoid cells in the peripheral blood. These cells express pan-B cell markers and high levels of surface immunoglobulin, and are CD5 negative in two-thirds of cases and almost always negative for CD10. Cases of mantle cell lymphoma masquerading as B-PLL must be excluded, particularly in suspected B-PLL cases that express CD5. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of B-PLL includes other chronic lymphoid neoplasms with a leukemic presentation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival is usually three to five years despite therapy. Prognostic markers have been difficult to determine, but anemia, thrombocytopenia, advanced age, and the presence of p53 mutations appear to predict a poor outcome. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/1\">",
"      Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/2\">",
"      Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/3\">",
"      Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     Catovsky D, Foa R. The Lymphoid Leukaemias, Butterworths, London 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/6\">",
"      Stone RM. Prolymphocytic leukemia. Hematol Oncol Clin North Am 1990; 4:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/7\">",
"      Bearman RM, Pangalis GA, Rappaport H. Prolymphocytic leukemia: clinical, histopathological, and cytochemical observations. Cancer 1978; 42:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/8\">",
"      Galton DA, Goldman JM, Wiltshaw E, et al. Prolymphocytic leukaemia. Br J Haematol 1974; 27:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/9\">",
"      Lampert I, Catovsky D, Marsh GW, et al. The histopathology of prolymphocytic leukaemia with particular reference to the spleen: a comparison with chronic lymphocytic leukaemia. Histopathology 1980; 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/10\">",
"      Del Giudice I, Davis Z, Matutes E, et al. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia 2006; 20:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/11\">",
"      Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood 1997; 89:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/12\">",
"      Lens D, Coignet LJ, Brito-Babapulle V, et al. B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene. Leukemia 1999; 13:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/13\">",
"      Sol&eacute; F, Woessner S, Espinet B, et al. Cytogenetic abnormalities in three patients with B-cell prolymphocytic leukemia. Cancer Genet Cytogenet 1998; 103:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/14\">",
"      Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol 2004; 125:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/15\">",
"      Del Giudice I, Osuji N, Dexter T, et al. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia 2009; 23:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20358/abstract/16\">",
"      Hercher C, Robain M, Davi F, et al. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 2001; 42:981.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4747 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20358=[""].join("\n");
var outline_f19_56_20358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Peripheral blood and bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16450299\">",
"      Splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4747|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/32/4615\" title=\"picture 1\">",
"      B cell leukemias morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/12/43207\" title=\"picture 2\">",
"      Prolymph leukemia marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/47/41719\" title=\"picture 3\">",
"      B-PLL spleen histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/55/31612\" title=\"table 1\">",
"      DDx BPLL path",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_56_20359="Cardiac causes of cyanosis in the newborn";
var content_f19_56_20359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac causes of cyanosis in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20359/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20359/contributors\">",
"     Robert L Geggel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20359/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20359/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20359/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20359/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20359/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/56/20359/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital heart disease (CHD) is the most common group of congenital disorders with a reported prevalence that ranges from six to thirteen per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Cyanotic cardiac lesions account for approximately 15 percent of all CHD cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/1\">",
"     1",
"    </a>",
"    ] and one-third of potentially fatal forms of CHD (critical CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Thus, early recognition, emergent stabilization, and transport to a cardiac care center with expertise in the management of cyanotic CHD are important to improve the outcome of affected patients.",
"   </p>",
"   <p>",
"    The causes of cyanotic CHD in the newborn are presented here. The diagnosis and initial management of infants with cyanotic CHD are discussed separately. In addition, the presentation and screening of critical CHD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"     \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF CYANOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis is a bluish discoloration of the tissues that results when the absolute level of reduced hemoglobin in the capillary bed exceeds 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The appearance of cyanosis depends upon the total amount of reduced hemoglobin rather than the ratio of reduced to oxygenated hemoglobin.",
"   </p>",
"   <p>",
"    Two mechanisms result in cyanosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central cyanosis is a pathologic conditions caused by systemic arterial oxygen desaturation. Cyanosis is visually perceptible when reduced hemoglobin exceeds 3",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      which generally corresponds to an oxygen saturation level below 85 percent in a patient with a hemoglobin concentration of 15",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Cyanosis may not be apparent in patients with anemia as oxygen saturation would need to be &lt;70 percent in a patient with a hemoglobin concentration of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef70325 \" href=\"UTD.htm?6/21/6494\">",
"       figure 1",
"      </a>",
"      ). Patients with cyanotic CHD have central cyanosis.",
"      <br/>",
"      <br/>",
"      Central cyanosis is best detected in highly vascularized tissues, such as the lips, mucous membranes, nail beds, and conjunctivae, through which blood flow is brisk and the arteriovenous difference is minimal. Cardiac output typically is normal, and patients have warm extremities.",
"     </li>",
"     <li>",
"      Peripheral cyanosis is due to increased tissue oxygen extraction in patients with normal systemic arterial oxygen saturation that leads to a widened systemic arteriovenous oxygen difference of 60 percent (from the normal 40 percent) resulting in an increased concentration of reduced hemoglobin on the venous side of the capillary bed. The increased oxygen extraction generally results from sluggish movement of blood through the capillary circulation. Causes include vasomotor instability, vasoconstriction caused by exposure to cold, venous obstruction, elevated venous pressure, polycythemia, and low cardiac output. Peripheral cyanosis typically affects the distal extremities and circumoral or periorbital areas [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/5\">",
"       5",
"      </a>",
"      ]. The extremities are often cool or clammy. Peripheral cyanosis may be associated with sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several factors that can affect the detection of cyanosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin concentration",
"     </li>",
"     <li>",
"      Fetal hemoglobin",
"     </li>",
"     <li>",
"      Skin pigmentation",
"     </li>",
"     <li>",
"      Physiologic factors that affect the oxygen dissociation curve such as alkalosis, acidosis, cold temperature, and low levels of 2,3 diphosphoglycerate (",
"      <a class=\"graphic graphic_figure graphicRef59739 \" href=\"UTD.htm?30/36/31310\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed description of how these factors affect the detection of cyanosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17513?source=see_link&amp;anchor=H95089272#H95089272\">",
"     \"Overview of cyanosis in the newborn\", section on 'Central versus peripheral cyanosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17513?source=see_link\">",
"     \"Overview of cyanosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia, with decreased arterial oxygen saturation leading to central cyanosis, results from the following mechanisms (",
"    <a class=\"graphic graphic_table graphicRef50161 \" href=\"UTD.htm?18/6/18540\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/5\">",
"     5",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link&amp;anchor=H9#H9\">",
"     \"Oxygenation and mechanisms of hypoxemia\", section on 'Mechanisms of hypoxemia'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right-to-left shunting of deoxygenated blood to the systemic circulation at the intracardiac, great vessel, or intrapulmonary level",
"     </li>",
"     <li>",
"      Ventilation-perfusion mismatch",
"     </li>",
"     <li>",
"      Alveolar hypoventilation",
"     </li>",
"     <li>",
"      Hemoglobinopathy that limits oxygen transport",
"     </li>",
"     <li>",
"      Diffusion impairment of oxygen from the alveolus to the pulmonary capillary",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Noncardiac causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncardiac causes of neonatal cyanosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary disorders are the most common causes of central cyanosis and include structural abnormalities of the lung, ventilation-perfusion mismatching, congenital or acquired airway obstruction, pneumothorax, and hypoventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"       \"Overview of neonatal respiratory distress: Disorders of transition\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal forms of hemoglobin (eg, methemoglobinemia (",
"      <a class=\"graphic graphic_figure graphicRef58540 \" href=\"UTD.htm?16/60/17344\">",
"       figure 3",
"      </a>",
"      )) can result in cyanosis (",
"      <a class=\"graphic graphic_table graphicRef72527 \" href=\"UTD.htm?40/51/41787\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/8\">",
"       8",
"      </a>",
"      ], and polycythemic infants may appear cyanotic even if they are adequately oxygenated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"       \"Genetic disorders of hemoglobin oxygen affinity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link\">",
"       \"Neonatal polycythemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor peripheral perfusion may result from sepsis, hypoglycemia, dehydration, and hypoadrenalism.",
"     </li>",
"     <li>",
"      Right-to-left shunting through the ductus arteriosus, resulting in a differential between SaO2 measured in the arm (preductal) and leg (postductal) can occur with primary or persistent pulmonary hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac causes of central cyanosis are a result of right-to-left shunting and can be further classified using different systems. In this review, cyanotic cardiac lesions are separated into the following physiologic categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased pulmonary blood flow",
"     </li>",
"     <li>",
"      Increased pulmonary blood flow",
"     </li>",
"     <li>",
"      Severe heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A frequently used mnemonic to identify five of the more common cyanotic lesions is the \"five Ts\" of cyanotic CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transposition of the great arteries",
"     </li>",
"     <li>",
"      Tetralogy of Fallot",
"     </li>",
"     <li>",
"      Truncus arteriosus",
"     </li>",
"     <li>",
"      Total anomalous pulmonary venous connection",
"     </li>",
"     <li>",
"      Tricuspid valve abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sixth \"T\" is often added for \"tons\" of other diseases, such as double outlet right ventricle, pulmonary atresia, multiple variations of single ventricle, hypoplastic left heart syndrome, complex conditions associated with heterotaxy syndromes, or anomalous systemic venous connection (left superior vena cava connected to the left atrium).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DECREASED PULMONARY BLOOD FLOW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanotic lesions with decreased pulmonary blood flow include tetralogy of Fallot, tricuspid valve anomalies, pulmonary valve atresia, and critical valvar pulmonary stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tetralogy of Fallot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetralogy of Fallot is a constellation of four anatomic defects consisting of an overriding aorta, right ventricular hypertrophy, pulmonary stenosis, and malalignment ventricular septal defect (VSD) (",
"    <a class=\"graphic graphic_figure graphicRef82493 \" href=\"UTD.htm?39/35/40501\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78997 \" href=\"UTD.htm?18/50/19232\">",
"     image 1",
"    </a>",
"    ). The clinical presentation depends upon the degree of pulmonary stenosis. More severe stenosis leads to greater reduction of pulmonary blood flow and increased cyanosis. Treatment of this congenital defect involves surgical closure of the VSD as well as repair of the pulmonary stenosis. The timing of this procedure depends upon the degree of obstruction to pulmonary blood flow.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of tetralogy of Fallot are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"     \"Overview of the management of tetralogy of Fallot\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulmonary valve atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary atresia with a VSD and normal tricuspid valve is usually considered to be a severe form of tetralogy of Fallot. Pulmonary atresia with an intact ventricular septum is often accompanied by tricuspid valve hypoplasia.",
"   </p>",
"   <p>",
"    In both lesions, the presence of pulmonary atresia means that the pulmonary blood flow is ductal dependent, that is, it depends upon blood flowing from the aorta to the pulmonary artery through a patent ductus arteriosus.",
"   </p>",
"   <p>",
"    In some cases, the pulmonary valve may be opened by cardiac catheterization, but the majority of patients with pulmonary atresia require surgical repair to establish a right ventricular to pulmonary artery connection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Critical valvar pulmonary stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical valvar pulmonary stenosis is also dependent on a patent ductus arteriosus for adequate pulmonary perfusion. The majority of these lesions are amenable to balloon dilation of the pulmonary valve via cardiac catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=see_link&amp;anchor=H6#H6\">",
"     \"Natural history and treatment of pulmonic stenosis\", section on 'Severe stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172998766\">",
"    <span class=\"h2\">",
"     Tricuspid valve anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid valve anomalies include tricuspid atresia, tricuspid stenosis, and Ebstein's anomaly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In tricuspid atresia, there is no communication between the right atrium and right ventricle that results in a total and obligatory right-to-left atrial shunt. Other abnormalities may be present including ventricular septal defect, pulmonary stenosis or transposition of the great arteries. The timing of surgical intervention depends on the degree of cyanosis and level of pulmonary flow.",
"     </li>",
"     <li>",
"      Tricuspid stenosis is usually seen with hypoplastic right ventricle and atrial septal defect. This also results in an atrial level right-to-left shunt.",
"     </li>",
"     <li>",
"      Ebstein's anomaly is a malformation of the tricuspid valve (",
"      <a class=\"graphic graphic_figure graphicRef79822 \" href=\"UTD.htm?20/36/21061\">",
"       figure 5",
"      </a>",
"      ). The variation in clinical severity is related to the extent of the inferior displacement of the tricuspid leaflets from the tricuspid annulus. In the most serious form of this defect, the tricuspid valve is severely deformed, displaced into the right ventricular outflow tract, and becomes increasingly insufficient. As a result, the right ventricular cavity size is reduced, and right ventricular outflow obstruction may result. Tricuspid regurgitation increases right atrial size and the diameter of a patent foramen ovale. Cyanosis results from right-to-left shunting at the atrial level but typically improves as pulmonary vascular resistance decreases in the neonatal transition period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"       \"Ebstein's anomaly of the tricuspid valve\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INCREASED PULMONARY BLOOD FLOW",
"    </span>",
"    &nbsp;&mdash;&nbsp;CHD that presents with cyanosis with increased pulmonary blood flow includes D-transposition of the great arteries, truncus arteriosus, and total anomalous pulmonary venous connection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     D-Transposition of the great arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transposition of the great arteries (TGA) is a ventriculoarterial discordant lesion in which the aorta arises from the right ventricle and the pulmonary artery from the left ventricle (",
"    <a class=\"graphic graphic_figure graphicRef68589 \" href=\"UTD.htm?12/51/13106\">",
"     figure 6",
"    </a>",
"    ). The most common form of TGA is the dextro type, in which the origin of the aorta is anterior and rightward to the pulmonary artery origin. This creates two parallel circulations that result in cyanotic heart disease. The first sends deoxygenated systemic venous blood to the right atrium and back to the systemic circulation via the right ventricle and aorta, and the second sends oxygenated pulmonary venous blood to the left atrium and back to the pulmonary circulation via the left ventricle and pulmonary artery.",
"   </p>",
"   <p>",
"    In infants with D-TGA, &nbsp;survival depends upon mixing of these two circulations, which occurs at the level of the atria (patent foramen ovale [PFO]), ventricles (approximately one-third of patients also have a ventricular septal defect), or great vessels (PDA). Balloon atrial septostomy, a procedure that can be performed in the cardiac catheterization laboratory or at the bedside with echocardiographic imaging, increases atrial mixing and typically dramatically increases systemic oxygenation. Following this procedure, an arterial switch operation is performed. This surgical repair effectively creates two serial circulatory systems.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of D-TGA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link\">",
"     \"Management and outcome of D-transposition of the great arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Truncus arteriosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Truncus arteriosus is a condition in which a single great vessel arises from the heart . The aorta, pulmonary arteries, and coronary arteries all originate from the ascending portion of this single vessel. There is always an associated ventricular septal defect. The single semilunar valve contains from three to six cusps and may be regurgitant. The prevalence of truncus arteriosus in the United States is estimated to be 0.8 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various subtypes of truncus arteriosus relate to the branching pattern of the pulmonary arteries. The aorta contains combined output from the left and right ventricles resulting in cyanosis, which may be mild if pulmonary vascular resistance is low and pulmonary blood is excessive. In that case, cyanosis may not be visible. This lesion also requires surgical correction within the first weeks of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2809?source=see_link\">",
"     \"Truncus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Total anomalous pulmonary venous connection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total anomalous pulmonary venous connection (TAPVC), also referred to as total pulmonary venous return (TAPVR), is a cyanotic congenital defect in which all four pulmonary veins fail to make their normal connection to the left atrium. This results in drainage of all pulmonary venous return into the systematic venous circulation. The clinical manifestations, diagnosis, and management of TAPVC and its variants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=see_link\">",
"     \"Total anomalous pulmonary venous connection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that present with cyanosis and heart failure include left sided obstructive lesions such as hypoplastic left heart syndrome, severe coarctation of the aorta, interrupted aortic arch, and critical valvar aortic stenosis. These obstructive left-sided heart lesions depend upon a patent ductus arteriosus to supply systemic flow. As the ductus closes, cyanosis, pulmonary edema, metabolic acidosis, and hypotension develop (neonatal shock). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H270523895#H270523895\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Ductal dependent lesions, delayed diagnosis, and death'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707575#H2707575\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Early serious or life-threatening presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link\">",
"     \"Etiology and diagnosis of heart failure in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5386?source=see_link\">",
"     \"Management of heart failure in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hypoplastic left heart syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoplastic left heart syndrome (HLHS) consists of a number of defects involving underdevelopment of the left-sided chambers and valves. Most commonly there is aortic valve atresia, severe mitral valve stenosis, and marked hypoplasia of the left ventricle. In HLHS, right-to-left shunting via the patent ductus arteriosus provides retrograde perfusion of the ascending and transverse portions of the aorta so that the subclavian, carotid, and coronary arteries are supplied.",
"   </p>",
"   <p>",
"    If untreated, 95 percent of neonates with HLHS die within the first few weeks of life. With the advancement of medical therapy (eg, prostaglandin E1 therapy) and introduction of a three staged palliative surgical procedures, survival has improved.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of HLHS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41401?source=see_link\">",
"     \"Hypoplastic left heart syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Coarctation of the aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta is a discrete narrowing of the aorta, which typically involves a thoracic preductal location distal to the left subclavian artery (",
"    <a class=\"graphic graphic_figure graphicRef62095 \" href=\"UTD.htm?40/3/41014\">",
"     figure 7",
"    </a>",
"    ). Infants with a severe coarctation of the aorta may present with heart failure when the ductus arteriosus closes.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and management of coarctation of the aorta are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link\">",
"     \"Management of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Interrupted aortic arch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extreme form of coarctation is an interrupted aortic arch. Complete interruption usually occurs between the left carotid and left subclavian arteries but can occur distal to the left subclavian artery or between the innominate artery and left carotid artery, and is usually associated with a large, non-restrictive ventricular septal defect. Surgical correction is required for both the arch obstruction and the ventricular septal defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Critical valvar aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe left ventricular outflow tract obstruction due to critical valvar aortic stenosis results in cyanosis and heart failure or even cardiogenic shock. Affected infants may have a soft murmur and minimal gradient by Doppler echocardiography because of severe left ventricular function and poor cardiac output. The intensity of the murmur may increase after successful intervention by balloon valvuloplasty or surgical repair due to improvement in left ventricular function and increased forward flow across the valve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link&amp;anchor=H6#H6\">",
"     \"Valvar aortic stenosis in children\", section on 'Critical AS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL CYANOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain congenital heart defects create differential cyanosis, in which the upper half of the body is pink and the lower half cyanotic, or vice versa. To detect differential cyanosis, oxygen saturation should be measured in sites that receive blood flow from both preductal (right hand) and postductal (foot) vessels. It is preferable to use the right (rather than left) upper extremity, since the left subclavian artery arises close to the ductus arteriosus, and some of its flow may come from the ductus and thus not accurately reflect preductal values.",
"   </p>",
"   <p>",
"    With normally related great arteries, oxygen saturation may be higher in the upper than lower extremity in patients if there is right-to-left shunting through the ductus arteriosus. This requires elevation of the pulmonary vascular resistance to a systemic level and a patent ductus arteriosus. The differential effect is reduced if there is also right-to-left shunting at the level of the foramen ovale, or if there is left-to-right shunting across a coexisting ventricular septal defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20359/abstract/2\">",
"     2",
"    </a>",
"    ]. Differential cyanosis can occur in patients with severe coarctation of the aorta or interrupted aortic arch. It may also occur in patients with structurally normal hearts who have persistent pulmonary hypertension of the newborn. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Reversed differential cyanosis is a rare finding that may occur in patients with transposition of the great arteries associated with either coarctation or pulmonary hypertension. In these infants, oxygen saturation is higher in the lower than upper extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/15/242?source=see_link\">",
"       \"Patient information: Total anomalous pulmonary venous connection in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172999188\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanotic cardiac lesions account for approximately 15 percent of all congenital heart disease (CHD) and one-third of potentially fatal cases of CHD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyanosis is a bluish discoloration of the tissues that results when the absolute level of reduced hemoglobin in the capillary bed exceeds 3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Patients with cyanotic CHD have central cyanosis caused by a reduction in arterial oxygen saturation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of cyanosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cyanotic cardiac lesions can be classified based on their physiology as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decreased pulmonary blood flow &ndash; Tetralogy of Fallot, pulmonary valve atresia, critical valvar pulmonary stenosis, and tricuspid valve anomalies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Decreased pulmonary blood flow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased pulmonary blood flow &ndash; Transposition of the great arteries, truncus arteriosus, and total anomalous pulmonary venous connection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Increased pulmonary blood flow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heart failure &ndash; As the ductus arteriosus closes, severe obstructive left-sided heart lesions may present with heart failure that is accompanied by cyanosis, pulmonary edema, metabolic acidosis, and hypotension. These lesions include hypoplastic left heart syndrome, coarctation and interruption of the aorta, and critical valvar aortic stenosis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A frequently used mnemonic to identify five of the more common cyanotic diseases is the \"five Ts\" of cyanotic CHD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transposition of the great arteries",
"     </li>",
"     <li>",
"      Tetralogy of Fallot",
"     </li>",
"     <li>",
"      Truncus arteriosus",
"     </li>",
"     <li>",
"      Total anomalous pulmonary venous connection",
"     </li>",
"     <li>",
"      Tricuspid valve abnormalities",
"      <br/>",
"      <br/>",
"      A sixth \"T\" is often added for \"tons\" of other diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differential cyanosis, in which the upper half of the body is pink and the lower half cyanotic, may be a finding in patients with severe coarctation of the aorta and interrupted aortic arch. In addition, infants with persistent pulmonary hypertension of the newborn and structurally normal hearts may also present with differential cyanosis. Reversed differential cyanosis is rare and may be seen in patients with transposition of the great arteries associated with either coarctation or pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Differential cyanosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26318659\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Laurie Armsby, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/1\">",
"      Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153:807.",
"     </a>",
"    </li>",
"    <li>",
"     Duff DF, McNamara DG. History and physical examination of the cardiovascular system. In: The science and practice of pediatric cardiology, Garson A Jr, Bricker TM, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.693.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/3\">",
"      Report of the New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/4\">",
"      Wren C, Reinhardt Z, Khawaja K. Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations. Arch Dis Child Fetal Neonatal Ed 2008; 93:F33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/5\">",
"      Lees MH. Cyanosis of the newborn infant. Recognition and clinical evaluation. J Pediatr 1970; 77:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/6\">",
"      Marino BS, Bird GL, Wernovsky G. Diagnosis and management of the newborn with suspected congenital heart disease. Clin Perinatol 2001; 28:91.",
"     </a>",
"    </li>",
"    <li>",
"     Nadas AS, Fyler DC. Hypoxemia. In: Nadas' Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, and Fyler DC (Eds), Saunders Elsevier, Philadelphia 2006. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/8\">",
"      Vichinsky EP, Lubin BH. Unstable hemoglobins, hemoglobins with altered oxygen affinity, and m-hemoglobins. Pediatr Clin North Am 1980; 27:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20359/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Improved national prevalence estimates for 18 selected major birth defects--United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2006; 54:1301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5780 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20359=[""].join("\n");
var outline_f19_56_20359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172999188\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF CYANOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Noncardiac causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DECREASED PULMONARY BLOOD FLOW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulmonary valve atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Critical valvar pulmonary stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172998766\">",
"      Tricuspid valve anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INCREASED PULMONARY BLOOD FLOW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      D-Transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Truncus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Interrupted aortic arch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Critical valvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIFFERENTIAL CYANOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172999188\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26318659\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5780|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/50/19232\" title=\"diagnostic image 1\">",
"      Chest xray tetralogy Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5780|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/21/6494\" title=\"figure 1\">",
"      Cyanosis and Hgb concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/36/31310\" title=\"figure 2\">",
"      Factors affecting neonatal oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/60/17344\" title=\"figure 3\">",
"      Acquired methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/35/40501\" title=\"figure 4\">",
"      Anatomy of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/36/21061\" title=\"figure 5\">",
"      Pathophysiology Ebstein anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/51/13106\" title=\"figure 6\">",
"      Dextro type of transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/3/41014\" title=\"figure 7\">",
"      Coarcation of the aorta anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/6/18540\" title=\"table 1\">",
"      Causes central cyanosis newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/51/41787\" title=\"table 2\">",
"      Causes of methemoglobinem",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41401?source=related_link\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=related_link\">",
"      Management and outcome of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=related_link\">",
"      Management of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5386?source=related_link\">",
"      Management of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=related_link\">",
"      Natural history and treatment of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17513?source=related_link\">",
"      Overview of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/15/242?source=related_link\">",
"      Patient information: Total anomalous pulmonary venous connection in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=related_link\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2809?source=related_link\">",
"      Truncus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_56_20360="Synovial fluid analysis and the diagnosis of septic arthritis";
var content_f19_56_20360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Synovial fluid analysis and the diagnosis of septic arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Dalton E Sholter, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Anthony S Russell, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20360/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/56/20360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid analysis may be diagnostic in patients with bacterial infections or crystal-induced synovitis. The white cell count, differential count, cultures, Gram stain, and crystal search using polarized light microscopy are the most valuable studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Noninflammatory fluids generally have fewer than 2000 white blood",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    with fewer than 75 percent polymorphonuclear leukocytes (",
"    <a class=\"graphic graphic_table graphicRef76506 \" href=\"UTD.htm?31/4/31820\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Suspected septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Rheumatology (ACR) clinical guidelines committee suggests that unexplained inflammatory fluid, particularly in a febrile patient, be assumed to be infected until proven otherwise by appropriate culture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the ACR committee, synovial fluid analysis should be performed in the febrile patient with an acute flare of established arthritis (eg, rheumatoid arthritis, osteoarthritis) to rule out superimposed septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated aspiration and synovial fluid analysis may be used to monitor the response of septic arthritis to treatment and may also be valuable for diagnosis of some cases of gout in which the initial aspirate does not have detectable crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Unexplained joint, bursa, or tendon sheath swelling",
"    </span>",
"    &nbsp;&mdash;&nbsp;When joint infection is thought to be unlikely, the main value of synovial fluid analysis is to permit classification into an inflammatory or noninflammatory category. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Categories of joint effusions'",
"    </a>",
"    below.) Thus, synovial fluid analysis should be performed if joint or other (eg, bursa, tendon sheath) synovial fluid is readily obtainable and if the diagnosis is uncertain after history, physical examination, and standard laboratory tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Suspected crystal-induced arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid analysis may be useful if sterile inflammation due to crystal disease is suspected, both in the acute setting and between attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid analysis in a patient with acute monoarticular or oligoarticular arthritis may reveal crystals of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD). In combination with a negative Gram stain and bacterial cultures, a diagnosis of gout or pseudogout may be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intercritical gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of synovial fluid may help confirm a clinical diagnosis of gout at a time when a patient has no symptoms or signs of active arthritis. During this \"intercritical period\" (ie, between attacks) monosodium urate crystals may still be present in synovial fluid. This was illustrated in a study of 43 synovial fluid aspirates obtained from patients who were not receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or uricosuric drugs during an intercritical period; all fluids had monosodium urate crystals identified by polarized microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Crystal search'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of gout\", section on 'Intercritical gout and recurrent gouty arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SYNOVIAL FLUID ASPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques for aspirating selected joints in adults and children are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=see_link\">",
"     \"Joint aspiration or injection in children: Indications, technique, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Specimen handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration is performed under aseptic conditions with the specimen for culture quickly transferred to sterile tubes and plated as soon as possible. If there is a large volume of synovial fluid, some may be inoculated into blood culture bottles, though data on the utility of this technique are limited. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Routine bacterial culture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Care must be taken not to contaminate the synovial fluid sample with injectable corticosteroid solutions, since steroid crystals may make the search for other crystals and the assessment of the Gram stain difficult.",
"   </p>",
"   <p>",
"    Inflammatory or hemorrhagic fluid, suggested by a hazy, opaque, or bloody appearance, may clot. Thus, if there is a sufficient volume of synovial fluid, transfer of at least 1 mL into a tube containing an anticoagulant may prevent clot formation and may facilitate an accurate cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/5\">",
"     5",
"    </a>",
"    ]. Either EDTA-containing or heparinized tubes used for blood collection may be used. Cell count and crystal search (see below) should be performed promptly as disintegration of cells and dissolution of crystals may occur over a matter of hours if the fluid is not refrigerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of talc-free gloves is recommended when preparing synovial fluid for a crystal search, as contamination of the slide with birefringent talc particles may make the microscopic examination for pathogenetically important crystals more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF SYNOVIAL FLUID",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normal synovial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal joints contain a small amount of synovial fluid with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Highly viscous",
"     </li>",
"     <li>",
"      Clear",
"     </li>",
"     <li>",
"      Essentially acellular",
"     </li>",
"     <li>",
"      Protein concentration approximately one-third that of plasma",
"     </li>",
"     <li>",
"      Glucose concentration similar to that in plasma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Categories of joint effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of synovial fluid analysis can be used to categorize the fluid as noninflammatory, inflammatory, septic, or hemorrhagic based upon the clinical and laboratory analysis (",
"    <a class=\"graphic graphic_table graphicRef76506 \" href=\"UTD.htm?31/4/31820\">",
"     table 1",
"    </a>",
"    ). The differential diagnosis of each of these specific categories is broad and not necessarily exclusive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninflammatory &mdash; Noninflammatory effusions may be caused by degenerative joint disease (such as osteoarthritis), trauma (including ligamentous or meniscal injuries), osteochondritis dissecans (osteonecrosis), neuropathic arthropathy, early or subsiding inflammation, or hypertrophic osteoarthropathy.",
"     </li>",
"     <li>",
"      Inflammatory &mdash; Inflammatory effusions may be caused by a large number of disorders including rheumatoid arthritis, acute crystal-induced synovitis (eg, gout, pseudogout), reactive arthritis (formerly Reiter syndrome), ankylosing spondylitis, psoriatic arthritis, arthritis associated with inflammatory bowel disease, rheumatic fever, systemic lupus erythematosus (SLE), sarcoidosis, hypertrophic osteoarthropathy, and systemic sclerosis. Rheumatic fever, SLE, chronic sarcoidosis, and scleroderma can also cause a noninflammatory effusion.",
"     </li>",
"     <li>",
"      Septic &mdash; Septic effusions may be due to bacteria, mycobacteria, or fungus. However, extremely elevated synovial WBC",
"      <span class=\"nowrap\">",
"       (&gt;100,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      are not always due to infection. Sterile processes that can cause this degree of leukocytosis, sometimes termed &ldquo;pseudoseptic arthritis,&rdquo; include reactions to intraarticular injections (eg, hyaluronans), flares of rheumatoid arthritis, leukemic infiltration, and gout [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemorrhagic &mdash; Hemorrhagic effusions may be caused by hemophilia, anticoagulation or other hemorrhagic diathesis, scurvy, trauma (with or without fracture), neuropathic arthropathy, and tumor (including pigmented villonodular synovitis, synovioma, hemangioma, and other benign or malignant neoplasms).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Characteristic synovial fluid abnormalities result from specific pathologic mechanisms which underlie the accumulation of joint fluid. As an example, when the synovial membrane becomes inflamed, there is an influx of white blood cells into the synovial tissue; the synovial membrane subsequently becomes leaky, thereby resulting in the exudation of plasma proteins into the synovial fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPONENTS OF SYNOVIAL FLUID ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to gross inspection of the characteristics of the synovial fluid, as noted above, the most valuable laboratory examinations on synovial fluid are the nucleated (or white blood) cell count, differential count, Gram stain, culture, and polarized microscopic search for crystals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gross appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume, clarity, color, and viscosity of joint fluid are noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clarity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased opacity of the fluid is usually due to abnormally large numbers of nucleated or red blood cells. However, translucent or even opaque fluid may be the result of acellular material. Examples include lipids in fat necrosis, cholesterol crystals in chylous effusions, or innumerable monosodium urate crystals aspirated from gouty tophi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Color",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorless, clear fluid is normal, while increasing amounts of plasma and nucleated cells contribute to the yellow or yellow-green appearance of inflammatory or septic fluids. Bright red, rusty, or chocolate brown fluids are indicative of fresh or old blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Viscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As joint fluid is expelled from the syringe and allowed to drop into a suitable receptacle, normal fluid will produce a long string-like extension as it falls. Release of proteolytic enzymes into inflamed synovial fluid typically causes a decrease in viscosity. However, frankly purulent (septic) effusions may also be viscous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Microscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microscopic examination of synovial fluid may be performed on as little as one drop of uncentrifuged fluid (wet mount); however, examination of the sediment of a centrifuged specimen may improve the sensitivity of the microscopic examination for crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/9\">",
"     9",
"    </a>",
"    ]. The sediment is also more adherent to glass microscope slides than unspun synovial fluid and may provide a better sample for preparation of the Gram stain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Nucleated (white) cell count and differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, inflammatory joint fluids often contain increased amounts of fibrinogen and fibrin and may clot during transport to the laboratory or while awaiting testing. Obtaining an accurate count of nucleated cells in synovial fluid is facilitated by placing some fluid in an anticoagulant-containing tube. If there is too little fluid to allow its transfer into a tube containing an anticoagulant, expedited transport to, and handling by, the laboratory may improve the likelihood of a technically satisfactory cell count.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell count &mdash; Normal synovial fluid is nearly acellular. Inflammatory and septic synovial fluids are characterized by increasing numbers of leukocytes. Bacterial joint infections typically are purulent with leukocyte counts (most of which are neutrophils) of 50,000 to 150,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      Substantial inter-laboratory variability has been noted in reported cell counts on aliquots of the same specimen [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If there is too little fluid to submit to the laboratory for a formal cell count, an estimate of the nucleated cell count may be feasible from the examination of a drop of fresh synovial fluid. Examination of 10 high power fields and the finding that there are zero to two nucleated cells per field is correlated with nucleated cell counts of",
"      <span class=\"nowrap\">",
"       &lt;1300/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A 2007 systematic review of the predictive ability of diagnostic tests for septic arthritis in adults presenting with acute mono- or oligoarthritis concluded that the likelihood of septic arthritis increases with the observed synovial fluid white cell count [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/14\">",
"       14",
"      </a>",
"      ]. In adults, as the synovial leukocyte count increased from",
"      <span class=\"nowrap\">",
"       25,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      to over",
"      <span class=\"nowrap\">",
"       50,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or to over",
"      <span class=\"nowrap\">",
"       100,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      the positive likelihood ratio (+LR) increased from 2.9 to 7.7 and to 28, respectively.",
"      <br/>",
"      <br/>",
"      Conversely, the likelihood of septic arthritis is modestly reduced in the setting of a synovial leukocyte count of less than",
"      <span class=\"nowrap\">",
"       25,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (estimated +LR 0.32) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/14\">",
"       14",
"      </a>",
"      ]. However, lower cell counts may be observed among immunocompromised patients with septic arthritis and in infections due to mycobacterial, some Neisserial, and several Gram positive organisms.",
"     </li>",
"     <li>",
"      Nucleated cell differential &mdash; In normal synovial fluid or in noninflammatory joint effusions, polymorphonuclear (PMN) leukocytes represent a small proportion of the nucleated cells present. Inflammatory and septic fluids have increasing proportions of PMNs present. Bacterial joint infections often have &ge;75 percent PMNs [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Eosinophilia in the synovial fluid suggests parasitic infection, allergy, neoplasm, or Lyme disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Other unusual features may also be apparent on the smear used for the differential cell count, including phagocytosis of nuclear material and the lupus erythematosus-cell phenomenon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malignant appearing cells may be noted in synovial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/17\">",
"     17",
"    </a>",
"    ]. However, if there is a suspicion of joint involvement by a neoplasm or hematologic malignancy, formal cytologic examination is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Crystal search",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of synovial fluid for monosodium urate (MSU) crystals and calcium pyrophosphate dihydrate (CPPD) crystals is facilitated by having a microscope with polarizing filters and a quarter wave plate (also known as a \"red compensator\").",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birefringence &mdash; Birefringence is a term used to describe the optical property associated with certain transparent crystals in which the speed of propagation of light along the major and minor axes of the crystal differs, causing the plane of polarized light to be rotated.",
"      <br/>",
"      <br/>",
"      Detection of birefringent crystals is facilitated by use of two plane polarizing filters, one between the light source and the sample and the other between the sample and the observer's eye. When the polarized filters are crossed, the background appears dark and birefringent material including MSU and CPPD crystals appear brighter than the background.",
"      <br/>",
"      <br/>",
"      An initial survey using a low power objective lens can give a rapid assessment of whether or not crystals are present and may identify areas of the specimen for closer inspection. Under high power magnification (eg, 400-fold), MSU crystals appear needle shaped and are strongly birefringent. In contrast, CPPD crystals appear rhomboidal or rectangular and are weakly birefringent.",
"      <br/>",
"      <br/>",
"      The red compensator is used to determine the direction of birefringence. Microscopes equipped with a red compensator will have the axis used for crystal analysis marked with an &ldquo;S,&rdquo; &ldquo;Z,&rdquo; or similar symbol indicating the &ldquo;slow&rdquo; axis. Birefringent crystals appear blue or yellow depending upon their &ldquo;sign&rdquo; of birefringence (negative or positive) and upon their orientation with respect to the axis of the analyzer.",
"     </li>",
"     <li>",
"      MSU crystals &mdash; As noted, these are brightly birefringent when viewed with crossed polarized filters and are needle shaped. When the red compensator is introduced into the light path and is adjusted so that the background appears red, MSU crystals appear yellow when aligned parallel to the \"S\" or \"Z\" axis indicated on the analyzer (",
"      <a class=\"graphic graphic_picture graphicRef64391 \" href=\"UTD.htm?19/48/20237\">",
"       picture 1",
"      </a>",
"      ). MSU crystals are referred to as being &ldquo;negatively birefringent.&rdquo;",
"     </li>",
"     <li>",
"      CPPD crystals &mdash; CPPD crystals have a rhomboidal or rectangular shape and have positive birefringence. However, compared with MSU crystals, the birefringence is weaker, and some CPPD crystals may not appear birefringent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/18\">",
"       18",
"      </a>",
"      ]. A birefringent CPPD crystal appears blue when its long axis is parallel to the \"S\" or \"Z\" axis indicated on the analyzer (",
"      <a class=\"graphic graphic_picture graphicRef55730 \" href=\"UTD.htm?37/5/37981\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other crystals &mdash; Crystals other than MSU and CPPD may have a role in the pathogenesis of some diseases. Examples include crystals of cholesterol, hydroxyapatite, and basic calcium phosphate. Calcium containing crystals other than CPPD are generally too small to detect with optical microscopy. Rarely, other crystals (ie, monoclonal proteins) may be seen. Their analysis may be confirmed by x-ray crystallography and electron microscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lipids &mdash; Cholesterol crystals are sometimes noted in chronic inflammatory synovial fluids. Cholesterol crystals often appear as notched polygonal plates (",
"      <a class=\"graphic graphic_picture graphicRef74417 \" href=\"UTD.htm?36/26/37282\">",
"       picture 3",
"      </a>",
"      ). In contrast to cholesterol, neutral fat (lipid) droplets have a \"Maltese cross\" appearance when viewed with polarizing microscopy that is identical to that of lipid droplets seen in the urine sediment of patients with nephrotic syndrome (",
"      <a class=\"graphic graphic_picture graphicRef79604 \" href=\"UTD.htm?31/0/31758\">",
"       picture 4",
"      </a>",
"      ). When lipid droplets are present in synovial fluid, articular fracture should be suspected [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apatite (hydroxyapatite) crystals &mdash; Among the many techniques that have been used to detect apatite crystals (reviewed in [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/19\">",
"       19",
"      </a>",
"      ]), only light microscopy with alizarin red or von Kossa stains, which have an affinity for calcium containing crystals, are considered to be practical for clinical use [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/9\">",
"       9",
"      </a>",
"      ]. However, the sensitivity and specificity of microscopy using one or the other of these calcium stains is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sensitivity and specificity of crystal search",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-trained observers are able to accurately identify crystals if any are present [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/20\">",
"     20",
"    </a>",
"    ]. However, substantial variability has been noted among hospital laboratories in the ability to properly identify the presence or absence of MSU and CPPD crystals in synovial fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies of the performance of different hospital laboratories on the same synovial fluids (reviewed in [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/12\">",
"     12",
"    </a>",
"    ]) suggest that MSU crystals are more easily detected than CPPD crystals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MSU crystals &mdash; Reported sensitivity of routine laboratory crystal analysis for MSU crystals ranges from 63 to 78 percent, specificity ranges from 93 to 100 percent, and positive likelihood ratio (+LR) is 14 for a diagnosis of gout [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CPPD crystals &mdash; Routine laboratory sensitivity for CPPD crystals ranges from 12 to 83 percent, specificity ranges from 78 to 96 percent, and positive LR is 2.9 for a diagnosis of CPPD-associated arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the detrimental effects caused by delay in examining unrefrigerated fluids, storage of synovial fluid at 4&ordm;C for periods up to three days has little effect on the sensitivity or specificity of the crystal search. This was illustrated in a study of synovial fluid specimens that were examined shortly after they were obtained and again after 72 hours and after two months of refrigeration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/21\">",
"     21",
"    </a>",
"    ]. No crystals were seen in the refrigerated fluids that were not apparent in the initial examination. The sensitivity of crystal analysis may be affected by prolonged storage; 89 of 93 remained positive for MSU and 87 of 90 positive for CPPD after two months of refrigerated storage.",
"   </p>",
"   <p>",
"    Crystals of MSU and CPPD may be present in the same synovial fluid specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/22\">",
"     22",
"    </a>",
"    ]. They have been noted within the same cell [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synovial fluid Gram stain is an easily performed test that can provide immediate, useful information concerning the diagnosis and therapy (Gram positive versus Gram negative coverage) of septic arthritis. In addition to identifying common organisms, Gram stain may be the only evidence of infection with fastidious organisms that are not able to grow in culture. As noted above, if there is sufficient fluid available, centrifugation provides sediment that may make the staining process easier as the pellet is generally more adherent to the microscope slide than unspun fluid.",
"   </p>",
"   <p>",
"    Despite its utility, the sensitivity and specificity of synovial fluid Gram stain is not known precisely. In nongonococcal bacterial arthritis, the sensitivity of Gram stain has been estimated to range from 50 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/17\">",
"     17",
"    </a>",
"    ]. In gonococcal arthritis, the sensitivity is much lower, probably &lt;10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/17\">",
"     17",
"    </a>",
"    ]. The specificity of a positive result is high when performed and interpreted by an experienced clinician or technician [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, the Gram stain results are classic and easy to identify, as with multiple Gram positive cocci aspirated from an acutely swollen knee. However, common problems include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clumps of stain or cellular material and other debris simulating bacteria",
"     </li>",
"     <li>",
"      Incorrect blanching so that Gram positive organisms appear Gram negative or rarely vice versa",
"     </li>",
"     <li>",
"      The presence of crystals in the synovial fluid. Although this finding is often indicative of crystal-induced arthritis (as in gout), some patients have, as noted above, coexisting crystal and septic arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is, therefore, important that the clinician be familiar with the Gram stain technique and interpretation or at least should have access to laboratory facilities and personnel proficient in this task. Questionable results (eg, from slides prepared and read during the night) can be re-examined by an expert the following day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a clinical suspicion of joint infection, culture of synovial fluid should be requested. Unless there are clinical features that suggest gonococcal, mycobacterial, or fungal infection, routine bacterial culture for aerobic and anaerobic bacteria are appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Routine bacterial culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synovial fluid samples should be routinely sent for culture of the common nongonococcal causes of bacterial arthritis: staphylococci followed by streptococci and Gram negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .) These organisms are easily grown on routine culture media in the absence of concomitant antibiotic therapy. The diagnostic yield may be improved by inoculation of blood culture bottles, although the efficacy of this approach is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35059?source=see_link\">",
"     \"Microbiology specimen collection and transport\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotics should generally not be given prior to joint aspiration. In patients in whom antibiotics have been started before arthrocentesis, the likelihood of recovering a pathogenic microorganism from synovial fluid may be increased if the fluid is first inoculated into commercial culture systems that contain antibiotic-binding beads [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive synovial culture should be indicative of septic arthritis in 100 percent of cases if laboratory error and contamination can be excluded. However, the sensitivity of synovial culture is not precisely known because of the lack of an alternative gold standard. It is difficult to prove that infection is present if synovial fluid cultures are negative.",
"   </p>",
"   <p>",
"    Clinical judgment concerning institution of antimicrobial therapy becomes important when an unexpected culture result is obtained, especially if the culture is positive in only in one of several specimens. If, for example, a young man presents with fever and an acutely swollen knee and if the aspirate is clearly purulent and without crystals, then many would assume the presence of infection regardless of the Gram stain and initial culture results. False negative cultures can be seen with fastidious organisms, inadequate laboratory techniques, or prior antibiotic therapy. False positive results are less common, most often resulting from contamination of improperly handled specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Suspected gonococcal arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonococcal arthritis is a common cause of septic arthritis in which the organism cannot be cultured on routine culture media [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/28\">",
"     28",
"    </a>",
"    ]. Cultures of synovial fluid tend to be positive in less than 50 percent of cases of gonococcal arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected adults are sexually active individuals and typically present with fever, chills, skin lesions, polyarthralgias, and tenosynovitis evolving into a persistent monoarthritis or oligoarthritis. Septic arthritis may also occur in disseminated infection in neonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"     \"Disseminated gonococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link&amp;anchor=H15#H15\">",
"     \"Gonococcal infection in the newborn\", section on 'Disseminated infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The joint aspirate should be cultured for N. gonorrhoeae when the history is suggestive. The yield can be increased if plates of chocolate agar or Thayer-Martin medium are inoculated with synovial fluid at the bedside along with cultures from clinically appropriate sites (eg, the pharynx, urethra, cervix, rectum, and skin lesions). Incubation of culture plates in a 5 percent CO",
"    <sup>",
"     2",
"    </sup>",
"    atmosphere may improve the sensitivity for gonococcal, Haemophilus influenza, and other fastidious organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/11\">",
"     11",
"    </a>",
"    ]. Blood cultures are often positive in patients disseminated gonococcal infection presenting with tenosynovitis and skin lesions alone but are frequently negative if a joint effusion is present [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of polymerase chain reaction (PCR) techniques to detect gonococcal DNA in synovial fluid can increase the yield in culture-negative cases and has been used in an investigational setting to monitor the response to therapy. However, this technique is not yet widely available, and its cost-effectiveness remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Suspected Lyme arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologic agent for Lyme disease, Borrelia burgdorferi, usually cannot be cultured from synovial fluid. Establishing the diagnosis may be difficult unless there is a history of tick bite (which is often absent) and the characteristic skin rash (erythema migrans). Serologic testing and more investigational procedures, such as PCR for detection of B. burgdorferi DNA, have been used to confirm the diagnosis, but each of these tests can give misleading results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     When should cultures be sent for unusual organisms?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history may reveal clues suggesting the possibility of an unusual cause of septic arthritis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of tuberculosis exposure",
"     </li>",
"     <li>",
"      A history of trauma or an animal bite",
"     </li>",
"     <li>",
"      Travel to or living in an area endemic with fungal infections or Lyme disease",
"     </li>",
"     <li>",
"      The presence of immune suppression",
"     </li>",
"     <li>",
"      A monoarthritis that is refractory to conventional therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Tuberculous arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible presence of tuberculous arthritis should be considered in any patient with a persistent culture-negative oligoarthritis or monoarthritis. A history of exposure to tuberculosis and a positive skin test are helpful, but both may be absent in a substantial proportion of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/33\">",
"     33",
"    </a>",
"    ]. Ziehl-Neelsen stain of the synovial fluid to detect acid-fast bacilli is often negative with an estimated sensitivity of only 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/34\">",
"     34",
"    </a>",
"    ]. Cultures may take six to eight weeks before becoming positive.",
"   </p>",
"   <p>",
"    The highest diagnostic yield is reached with the triad of synovial fluid culture, staining for acid-fast bacilli, and histologic examination of the synovial membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/35\">",
"     35",
"    </a>",
"    ]. Rapid tests based on nucleic acid amplification are commercially available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Fungal arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insidious onset of monoarthritis, a pattern clinically indistinguishable from tuberculous arthritis, may indicate fungal infection. Clinical clues include trauma with possible sporotrichosis inoculation, travel to the southwestern United States where coccidioidomycosis is endemic, or immune deficiency which may predispose to candidal arthritis. In these settings, cultures should be sent for the appropriate organisms; synovial biopsies may be diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20360/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial fluid analysis may be diagnostic in patients with bacterial joint infection and crystal-induced arthritis. This analysis is indicated in febrile patients with an acute flare of already established arthritis and in other situations in which the cause of a joint effusion is uncertain or septic arthritis is suspected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Technical aspects of synovial fluid aspiration in adults and children are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"       \"Joint aspiration or injection in adults: Technique and indications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=see_link\">",
"       \"Joint aspiration or injection in children: Indications, technique, and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The volume of synovial fluid removed is noted along with the clarity, color, and viscosity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gross appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most valuable components of laboratory analysis of synovial fluid are the white cell count, differential count, cultures, Gram stain, and crystal search using polarized light microscopy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Components of synovial fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal synovial fluid is viscous, clear, colorless, and nearly acellular. We suggest categorizing abnormal synovial fluids into those that are noninflammatory, inflammatory, septic, and hemorrhagic as a means to reduce the number of possible causes of effusions to consider in the differential diagnosis. However, for each category, there is significant diagnostic overlap. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Characteristics of synovial fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gonococcal, Borrelial (Lyme disease), mycobacterial, or fungal joint infections should be suspected when routine bacterial cultures of synovial fluid do not yield a pathogenic organism. Additional diagnostic tests are suggested when these diseases are suspected. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/1\">",
"      Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/2\">",
"      Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests. What should be ordered? JAMA 1990; 264:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/3\">",
"      Schumacher HR, Jimenez SA, Gibson T, et al. Acute gouty arthritis without urate crystals identified on the initial examination of synovial fluid: report of 9 patients. Arthritis Rheum 1975; 18:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/4\">",
"      Pascual E, Batlle-Gualda E, Mart&iacute;nez A, et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999; 131:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/5\">",
"      Freemont AJ. Microscopic analysis of synovial fluid--the perfect diagnostic test? Ann Rheum Dis 1996; 55:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/6\">",
"      Kerolus G, Clayburne G, Schumacher HR Jr. Is it mandatory to examine synovial fluids promptly after arthrocentesis? Arthritis Rheum 1989; 32:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/7\">",
"      Dieppe P, Swan A. Identification of crystals in synovial fluid. Ann Rheum Dis 1999; 58:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/8\">",
"      Krey PR, Bailen DA. Synovial fluid leukocytosis. A study of extremes. Am J Med 1979; 67:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/9\">",
"      Chen LX, Clayburne G, Schumacher HR. Update on identification of pathogenic crystals in joint fluid. Curr Rheumatol Rep 2004; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/10\">",
"      Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985; 312:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/11\">",
"      Atkins BL, Bowler IC. The diagnosis of large joint sepsis. J Hosp Infect 1998; 40:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/12\">",
"      Swan A, Amer H, Dieppe P. The value of synovial fluid assays in the diagnosis of joint disease: a literature survey. Ann Rheum Dis 2002; 61:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/13\">",
"      Clayburne G, Baker DG, Schumacher HR Jr. Estimated synovial fluid leukocyte numbers on wet drop preparations as a potential substitute for actual leukocyte counts. J Rheumatol 1992; 19:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/14\">",
"      Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007; 297:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/15\">",
"      Kay J, Eichenfield AH, Athreya BH, et al. Synovial fluid eosinophilia in Lyme disease. Arthritis Rheum 1988; 31:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/16\">",
"      Dougados M. Synovial fluid cell analysis. Baillieres Clin Rheumatol 1996; 10:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/17\">",
"      Shmerling RH. Synovial fluid analysis. A critical reappraisal. Rheum Dis Clin North Am 1994; 20:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/18\">",
"      Ivorra J, Rosas J, Pascual E. Most calcium pyrophosphate crystals appear as non-birefringent. Ann Rheum Dis 1999; 58:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/19\">",
"      Molloy ES, McCarthy GM. Hydroxyapatite deposition disease of the joint. Curr Rheumatol Rep 2003; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/20\">",
"      Lumbreras B, Pascual E, Frasquet J, et al. Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis 2005; 64:612.",
"     </a>",
"    </li>",
"    <li>",
"     Schumacher HR, Reginato AJ. Atlas of synovial fluid analysis and crystal identification, Lea and Febiger, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/22\">",
"      Cruz J, Clayburne GM, Sieck MS, Schumacher HR. Coexistence of calcium pyrophosphate and monosodium urate crystals in synovial fluid. (abstract) Arthritis Rheum 2001; 44:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/23\">",
"      Baer PA, Tenenbaum J, Fam AG, Little H. Coexistent septic and crystal arthritis. Report of four cases and literature review. J Rheumatol 1986; 13:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/24\">",
"      Deesomchok U, Tumrasvin T. Clinical study of culture-proven cases of non-gonococcal arthritis. J Med Assoc Thai 1990; 73:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/25\">",
"      von Essen R, H&ouml;ltt&auml; A. Improved method of isolating bacteria from joint fluids by the use of blood culture bottles. Ann Rheum Dis 1986; 45:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/26\">",
"      Kortekangas P, Aro HT, Lehtonen OP. Synovial fluid culture and blood culture in acute arthritis. A multi-case report of 90 patients. Scand J Rheumatol 1995; 24:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/27\">",
"      Sorlin P, Mansoor I, Dagyaran C, Struelens MJ. Comparison of resin-containing BACTEC Plus Aerobic/F* medium with conventional methods for culture of normally sterile body fluids. J Med Microbiol 2000; 49:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/28\">",
"      Sharp JT, Lidsky MD, Duffy J, Duncan MW. Infectious arthritis. Arch Intern Med 1979; 139:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/29\">",
"      Wise CM, Morris CR, Wasilauskas BL, Salzer WL. Gonococcal arthritis in an era of increasing penicillin resistance. Presentations and outcomes in 41 recent cases (1985-1991). Arch Intern Med 1994; 154:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/30\">",
"      O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore) 1983; 62:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/31\">",
"      Liebling MR, Arkfeld DG, Michelini GA, et al. Identification of Neisseria gonorrhoeae in synovial fluid using the polymerase chain reaction. Arthritis Rheum 1994; 37:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/32\">",
"      Muralidhar B, Rumore PM, Steinman CR. Use of the polymerase chain reaction to study arthritis due to Neisseria gonorrhoeae. Arthritis Rheum 1994; 37:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/33\">",
"      Evanchick CC, Davis DE, Harrington TM. Tuberculosis of peripheral joints: an often missed diagnosis. J Rheumatol 1986; 13:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/34\">",
"      Wallace R, Cohen AS. Tuberculous arthritis: A report of two cases with review of biopsy and synovial fluid findings. Am J Med 1976; 61:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/35\">",
"      Ellis ME, el-Ramahi KM, al-Dalaan AN. Tuberculosis of peripheral joints: a dilemma in diagnosis. Tuber Lung Dis 1993; 74:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20360/abstract/36\">",
"      Cu&eacute;llar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis 1992; 51:690.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1828 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20360=[""].join("\n");
var outline_f19_56_20360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Suspected septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Unexplained joint, bursa, or tendon sheath swelling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Suspected crystal-induced arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intercritical gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SYNOVIAL FLUID ASPIRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Specimen handling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHARACTERISTICS OF SYNOVIAL FLUID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normal synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Categories of joint effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPONENTS OF SYNOVIAL FLUID ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gross appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clarity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Color",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Viscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Microscopic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Nucleated (white) cell count and differential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Crystal search",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sensitivity and specificity of crystal search",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Routine bacterial culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Suspected gonococcal arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Suspected Lyme arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - When should cultures be sent for unusual organisms?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Tuberculous arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Fungal arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1828\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1828|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20237\" title=\"picture 1\">",
"      Monosodium urate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/5/37981\" title=\"picture 2\">",
"      Intracellular CPPD crystal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/26/37282\" title=\"picture 3\">",
"      Crystals in synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/0/31758\" title=\"picture 4\">",
"      Fatty cast polarized",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1828|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/4/31820\" title=\"table 1\">",
"      Categories of synovial fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=related_link\">",
"      Joint aspiration or injection in children: Indications, technique, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35059?source=related_link\">",
"      Microbiology specimen collection and transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_56_20361="Quetiapine: Drug information";
var content_f19_56_20361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quetiapine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/29/15830?source=see_link\">",
"    see \"Quetiapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      SEROquel XR&reg;;",
"     </li>",
"     <li>",
"      SEROquel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quetiapine&reg;;",
"     </li>",
"     <li>",
"      CO Quetiapine;",
"     </li>",
"     <li>",
"      Dom-Quetiapine;",
"     </li>",
"     <li>",
"      JAMP-Quetiapine;",
"     </li>",
"     <li>",
"      Mylan-Quetiapine;",
"     </li>",
"     <li>",
"      PHL-Quetiapine;",
"     </li>",
"     <li>",
"      PMS-Quetiapine;",
"     </li>",
"     <li>",
"      PRO-Quetiapine;",
"     </li>",
"     <li>",
"      ratio-Quetiapine;",
"     </li>",
"     <li>",
"      Riva-Quetiapine;",
"     </li>",
"     <li>",
"      Sandoz-Quetiapine;",
"     </li>",
"     <li>",
"      Seroquel XR&reg;;",
"     </li>",
"     <li>",
"      Seroquel&reg;;",
"     </li>",
"     <li>",
"      Teva-Quetiapine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bipolar disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Depression:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release tablet: Initial: 50 mg once daily the first day; increase to 100 mg once daily on day 2, further increasing by 100 mg/day each day until a target dose of 300 mg once daily is reached by day 4. Further increases up to 600 mg once daily by day 8 have been evaluated in clinical trials, but no additional antidepressant efficacy was noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release tablet: Initial: 50 mg/day the first day; increase to 100 mg on day 2, further increasing by 100 mg/day each day until a target dose of 300 mg/day is reached by day 4.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mania:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release tablet: Initial: 50 mg twice daily on day 1, increase dose in increments of 100 mg/day to 200 mg twice daily on day 4; may increase to a target dose of 800 mg/day by day 6 at increments &le;200 mg/day. Usual dosage range: 400-800 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release tablet: Initial: 300 mg on day 1; increase to 600 mg on day 2 and adjust dose to 400-800 mg once daily on day 3, depending on response and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance therapy:",
"     </i>",
"     Immediate release tablet: 200-400 mg twice daily with lithium or divalproex;",
"     <b>",
"      Note:",
"     </b>",
"     Average time of stabilization was 15 weeks in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Major depressive disorder (adjunct to antidepressants):",
"     </b>",
"     Oral: Extended release tablet: Initial: 50 mg once daily; may be increased to 150 mg on day 3. Usual dosage range: 150-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychoses:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Initial: 25 mg twice daily; followed by increases in the total daily dose on the second and third day in increments of 25-50 mg divided 2-3 times/day, if tolerated, to a target dose of 300-400 mg/day in 2-3 divided doses by day 4. Make further adjustments as needed at intervals of at least 2 days in adjustments of 25-50 mg divided twice daily. Usual maintenance range: 300-800 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended-release tablet: Initial: 300 mg once daily; increase in increments of up to 300 mg/day (in intervals of &ge;1 day). Usual maintenance range: 400-800 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose reductions should be attempted periodically to establish lowest effective dose in patients with psychosis. Patients being restarted after 1 week of no drug need to be titrated as above.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ICU delirium:",
"     </b>",
"     Oral: Initial: 50 mg twice daily; may increase as necessary on a daily basis in increments of 50 mg twice daily to a maximum dose of 400 mg/day (Devlin, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Total daily doses may also be divided into 3 doses per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder:",
"     </b>",
"     Children &ge;10 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mania:",
"     </i>",
"     Immediate release tablet: Initial: 25 mg twice daily on day 1; increase to 50 mg twice daily on day 2, further increasing by 100 mg/day each day until a target dose of 400 mg/day is reached on day 5. May increase up to 600 mg/day at increments &le;100 mg/day; however, no additional benefit seen with 600 mg/day. Usual dosage range: 400-600 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance therapy:",
"     </i>",
"     Immediate release tablet: Continue therapy at lowest dose needed to maintain remission; periodically assess maintenance treatment needs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Autism (unlabeled use):",
"     </b>",
"     Children &ge;10 years: Oral: 100-350 mg/day (1.6-5.2 mg/kg/day) (Martin, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Adolescents &ge;13 years: Oral: Immediate release tablet: Initial: 25 mg twice daily on day 1; increase to 50 mg twice daily on day 2, further increasing by 100 mg/day each day until a target dose of 400 mg/day is reached on day 5. May increase up to 800 mg/day at increments &le;100 mg/day; however, no additional benefit seen with 800 mg/day. Usual dosage range: 400-800 mg/day; periodically assess maintenance treatment needs.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults &gt;65 years: 40% lower mean oral clearance of quetiapine in adults &gt;65 years of age; higher plasma levels expected and, therefore, dosage adjustment may be needed; elderly patients usually require 50-200 mg/day of immediate release tablets or 50 mg/day of extended release tablets with a slower titration schedule. Increase immediate release dose by 25-50 mg/day or extended release dose by 50 mg/day to effective dose, based on clinical response and tolerability. If initiated with immediate release tablets, patient may transition to extended release formulation (at equivalent total daily dose) when effective dose has been reached. See &ldquo;Note&rdquo; in adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Psychosis/agitation related to Alzheimer&rsquo;s dementia (unlabeled use): Initial: 12.5-50 mg/day; if necessary, gradually increase as tolerated not to exceed 200-300 mg/day (Rabins, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required: 25% lower mean oral clearance of quetiapine than normal subjects; however, plasma concentrations similar to normal subjects receiving the same dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F216277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower clearance in hepatic impairment (30%), may result in higher concentrations. Dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablet: Oral: Initial: 25 mg/day, increase dose by 25-50 mg/day to effective dose, based on clinical response and tolerability to patient. If initiated with immediate-release formulation, patient may transition to extended-release formulation (at equivalent total daily dose) when effective dose has been reached.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release tablet Oral: Initial: 50 mg/day; increase dose by 50 mg/day to effective dose, based on clinical response and tolerability to patient.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SEROquel&reg;: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SEROquel XR&reg;: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Seroquel&reg;: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Seroquel XR&reg;: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Seroquel&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089126.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089126.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Seroquel XR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM194582.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM194582.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5094101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release tablet: May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release tablet: Administer without food or with a light meal (&le;300 calories), preferably in the evening. Swallow tablet whole; do not break,  crush, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasogastric/enteral tube (unlabeled route): Hold tube feeds for 30 minutes before administration; flush with 25 mL of sterile water. Crush dose using immediate-release formulation, mix in 10 mL water and administer via NG/enteral tube; follow with a 50 mL flush of sterile water (Devlin, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia; treatment of acute manic or mixed episodes associated with bipolar I  disorder (as monotherapy or in combination with lithium or divalproex); maintenance treatment of bipolar I disorder (in combination with lithium or divalproex); treatment of acute depressive episodes associated with bipolar disorder; adjunctive treatment of major depressive disorder",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F216294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Autism; delirium in the critically-ill patient; psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       QUEtiapine may be confused with OLANZapine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SEROquel&reg; may be confused with Serzone, SINEquan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Actual frequency may be dependent upon dose and/or indication. Unless otherwise noted, frequency of adverse effects is reported for adult patients; spectrum and incidence of adverse effects similar in children (with significant exceptions noted).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Diastolic blood pressure increased (children and adolescents, 41%), systolic blood pressure increased (children and adolescents, 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (18% to 57%), headache (7% to 21%), agitation (5% to 20%), dizziness (1% to 18%), fatigue (3% to 14%), extrapyramidal symptoms (1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (&ge;200 mg/dL, 8% to 22%), HDL cholesterol decreased (&le;40 mg/dL, 6% to 19%), total cholesterol increased (&ge;240 mg/dL, 7% to 18%), LDL cholesterol increased (&ge;160 mg/dL, 4% to 17%), hyperglycemia (&ge;200 mg/dL post glucose challenge or fasting glucose &ge;126 mg/dL, 2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (9% to 44%), weight gain (dose related; 3% to 23%), appetite increased (2% to 12%), constipation (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (2% to 7%; children and adolescents &lt;1%), tachycardia (1% to 6%), syncope (&lt;5%), palpitation (4%), peripheral edema (4%), hypotension (3%), hypertension (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (9%), akathisia (&le;8%), pain (1% to 7%), dystonia (&le;6%), lethargy (1% to 5%), tardive dyskinesia (&lt;5%), anxiety (2% to 4%), irritability (1% to 4%), parkinsonism (&le;4%), abnormal dreams (2% to 3%), depression (1% to 3%), hypersomnia (1% to 3%), abnormal thinking (2%), ataxia (2%), attention disturbance (2%), coordination impaired (2%), disorientation (2%), hypoesthesia (2%), mental impairment (2%), migraine (2%), sluggishness (2%), vertigo (2%), confusion (1% to 2%), restlessness (1% to 2%), fever (1% to 2%), chills (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%), hyperhidrosis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperprolactinemia (4%), libido decreased (&le;2%), hypothyroidism (&le;2%), female lactation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7% to 8%), abdominal pain (dose related; 4% to 7%), dyspepsia (dose related; 2% to 7%), vomiting (1% to 6%), drooling (&lt;5%), gastroenteritis (2% to 4%),  toothache (2% to 3%), appetite decreased (2%), dysphagia (2%), flatulence (2%), GERD (2%), anorexia (&ge;1%), abnormal taste (1%), abdominal distension (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pollakiuria (2%), urinary tract infection (2%), impotence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (&le;2%), leukopenia (&ge;1%), hemorrhage (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (1% to 6%), GGT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2% to 10%), tremor (2% to 8%), back pain (3% to 5%), dysarthria (1% to 5%), hypertonia (4%), twitching (4%), dyskinesia (&le;4%), arthralgia (1% to 4%), paresthesia (3%), muscle spasm (1% to 3%), limb pain (2%), myalgia (2%), neck pain (2%), neck rigidity (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (1% to 4%), amblyopia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (4% to 6%), nasal congestion (5%), rhinitis (3% to 4%), upper respiratory tract infection (2% to 3%), sinus congestion (2%), sinus headache (2%), sinusitis (2%), cough (3%), dyspnea (&ge;1%), dry throat (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%), restless legs syndrome (2%), flu-like syndrome (1% to 2%), lymphadenopathy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, alkaline phosphatase increased, amnesia, anaphylactic reaction, anaphylaxis, anemia, angina, asthma, atrial arrhythmia, AV block, bradycardia, bundle branch block, cardiomyopathy, cataract formation, cerebral ischemia, cerebrovascular accident, HF, CPK increased, creatinine increased, dehydration, diabetes mellitus, dysuria, eosinophilia, epistaxis, exfoliative dermatitis, galactorrhea, hallucinations, hematemesis, hypersensitivity, hypoglycemia, hypokalemia, hyponatremia,  intestinal obstruction, involuntary movements, leukocytosis, myocarditis, neuroleptic malignant syndrome, nightmares, palpitation, pancreatitis, pneumonia, priapism, QRS duration increased, QT prolongation, rectal bleeding, rhabdomyolysis, seizure, SIADH, Stevens-Johnson syndrome, ST segment elevation, suicidal ideation, suicide attempt, thrombocytopenia, tinnitus, T-wave abnormal, T-wave inversion, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to quetiapine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor all patients for clinical worsening, suicidality, or unusual changes in behavior; particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increased or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants (for any indication) should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other antipsychotics, quetiapine has a moderate potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataracts: Use has been noted to cause cataracts in animals; lens changes have been observed in humans during long-term treatment.  Lens examination on initiation of therapy and every 6 months is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Increases in cholesterol and triglycerides have been noted. Use with caution in patients with pre-existing abnormal lipid profile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: May increase prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: May cause dose-related decreases in thyroid levels, including cases requiring thyroid replacement therapy. Reversal of thyroid effects occurred in almost all cases following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability. This risk in association with quetiapine is very low relative to other antipsychotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Rare cases of priapism have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Use has been associated with QT prolongation; postmarketing reports have occurred in patients with concomitant illness, quetiapine overdose, or who were receiving concomitant therapy known to affect QT interval or cause electrolyte imbalance. Avoid use in patients at increased risk of torsade de pointes/sudden death (eg, hypokalemia, hypomagnesemia, history of cardiac arrhythmias, congenital prolongation of QT interval, concomitant medications with QT",
"     <sub>",
"      c",
"     </sub>",
"     interval-prolonging properties). Use with caution in patients at increased risk of QT prolongation (eg, cardiovascular disease, heart failure, cardiac hypertrophy, elderly, family history of QT prolongation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating; use with caution in disorders where CNS depression is a feature. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction, ischemic heart disease, or hypercholesterolemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Quetiapine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; may increase transaminases (primarily ALT; transient, reversible). Substantial hepatic metabolism via CYP3A4; may require dose adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder.",
"     <b>",
"      Quetiapine is FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal disease; experience is limited.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients using immediate release tablets may be switched to extended release tablets at the same total daily dose taken once daily. Dosage adjustments may be necessary based on response and tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: Use caution when withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Abrupt cessation may cause (rarely) acute withdrawal symptoms (eg, nausea, vomiting, or insomnia).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of QUEtiapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of QUEtiapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F216266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: In healthy volunteers, administration of quetiapine (immediate release) with food resulted in an increase in the peak serum concentration and AUC by 25% and 15%, respectively, compared to the fasting state. Administration of the extended release formulation with a high-fat meal (~800-1000 calories) resulted in an increase in peak serum concentration by 44% to 52% and AUC by 20% to 22% for the 50 mg and 300 mg tablets; administration with a light meal (&le;300 calories) had  no significant effect on the C",
"     <sub>",
"      max",
"     </sub>",
"     or AUC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease quetiapine levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6831003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quetiapine was embryo and fetal toxic, but not teratogenic in animal reproduction studies. Congenital malformations have not been observed in humans (based on limited data). The long term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure on infant development and behavior are not known. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers, 2009). Healthcare providers are encouraged to enroll women 18-45 years of age exposed to quetiapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9850204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on information from 8 mother/infant pairs, concentrations of quetiapine in breast milk have been reported as 0-170 &mu;g/L. The estimated exposure to the breast-feeding infant would be up to 1 mg/kg/day (relative infant dose up to 0.43% based on a weight adjusted maternal dose of 400 mg/day).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F216256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Immediate-release tablet may be taken without regard to meals. Extended release tablet should be taken without food or with a light meal (&le;300 calories).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F216255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (SEROquel XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $460.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $827.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $910.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $1194.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $1403.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (QUEtiapine Fumarate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $399.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $656.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $685.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $1293.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $1017.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $1993.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SEROquel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $466.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $766.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $800.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $1509.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $1187.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $2325.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); CBC frequently during first few months of therapy in patients with pre-existing low WBC or a history of drug-induced leukopenia/neutropenia; BMI, personal/family history of obesity, waist circumference; mental status, abnormal involuntary movement scale (AIMS). Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. Patients should have eyes checked for cataracts every 6 months while on this medication. Observe for new or worsening depression, anxiety, irritability, aggression, or other symptoms of unusual behavior, mood, or suicide ideation (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cacepin (KP);",
"     </li>",
"     <li>",
"      Calm-EZ (TW);",
"     </li>",
"     <li>",
"      Hiloca (TW);",
"     </li>",
"     <li>",
"      Ketilept (PH);",
"     </li>",
"     <li>",
"      Ketipinor (MY, SG);",
"     </li>",
"     <li>",
"      Limus (TW);",
"     </li>",
"     <li>",
"      Neutapin (TH, TW);",
"     </li>",
"     <li>",
"      Q-Win (PH);",
"     </li>",
"     <li>",
"      Quantia (TW);",
"     </li>",
"     <li>",
"      Quetapel (NZ);",
"     </li>",
"     <li>",
"      Quetapin (KP);",
"     </li>",
"     <li>",
"      Quetiap RD (PH);",
"     </li>",
"     <li>",
"      Quetiazic (CR, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Quetidin (CO);",
"     </li>",
"     <li>",
"      Quety (KP);",
"     </li>",
"     <li>",
"      Qutipin (KP);",
"     </li>",
"     <li>",
"      Seroquel (AR, AT, AU, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CZ, DE, DK, DO, EC, EE, ES, FI, GB, GR, GY, HK, ID, IE, IL, IT, JM, KP, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PR, PT, PY, RU, SE, SR, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Seroquel IR (HK);",
"     </li>",
"     <li>",
"      Seroquel XR (AU, GB, HK, ID, IE, IL, MY, PH, SG, TH);",
"     </li>",
"     <li>",
"      Smoodipin (KP);",
"     </li>",
"     <li>",
"      Socalm (IN);",
"     </li>",
"     <li>",
"      Utapine (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quetiapine is a dibenzothiazepine atypical antipsychotic. It has been proposed that this drug's antipsychotic activity is mediated through a combination of dopamine type 2 (D",
"     <sub>",
"      2",
"     </sub>",
"     ) and serotonin type 2 (5-HT",
"     <sub>",
"      2",
"     </sub>",
"     ) antagonism. It is an antagonist at multiple neurotransmitter receptors in the brain: Serotonin 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     , dopamine D",
"     <sub>",
"      1",
"     </sub>",
"     and D",
"     <sub>",
"      2",
"     </sub>",
"     , histamine H",
"     <sub>",
"      1",
"     </sub>",
"     , and adrenergic alpha",
"     <sub>",
"      1",
"     </sub>",
"     - and alpha",
"     <sub>",
"      2",
"     </sub>",
"     -receptors;  but appears to have no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors. Norquetiapine, an active metabolite, differs from its parent molecule by exhibiting high affinity for muscarinic M1 receptors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antagonism at receptors other than dopamine and 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     with similar receptor affinities may explain some of the other effects of quetiapine. The drug's antagonism of histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -receptors may explain the somnolence observed. The drug's antagonism of adrenergic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -receptors may explain the orthostatic hypotension observed.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly absorbed following oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6-14 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; via CYP3A4; forms the metabolite N-desalkyl quetiapine (active) and two inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 100% (relative to oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mean: Terminal: Quetiapine: ~6 hours; Extended release: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolite: N-desalkyl quetiapine: 9-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Immediate release: 1.5 hours; Extended release: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (73% as metabolites, &lt;1% of total dose as unchanged drug); feces (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bauer M, Pretorius HW, Constant EL, et al, &ldquo;Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients with Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2009, 70(4):540-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/19358791/pubmed\" id=\"19358791\" target=\"_blank\">",
"        19358791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis JM, Chen N, and Glick ID, &ldquo;A Meta-analysis of the Efficacy of Second-Generation Antipsychotics,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2003, 60(6):553-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/12796218/pubmed\" id=\"12796218\" target=\"_blank\">",
"        12796218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DelBello MP, Schwiers ML, Rosenberg HL, et al, &ldquo;Quetiapine as Adjunctive Treatment for Adolescent Mania,&rdquo; Poster presented at Fourth International Conference on Bipolar Disorder, Pittsburgh, PA: Jun 14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devlin JW, Roberts RJ, Fong JJ, et al, &ldquo;Efficacy and Safety of Quetiapine in Critically Ill Patients With Delirium: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2010, 38(2):419-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/19915454/pubmed\" id=\"19915454\" target=\"_blank\">",
"        19915454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at file://www.psychiatryonline.com/content.aspx?aid=501001",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gentile S, \"Infant Safety With Antipsychotic Therapy in Breast-Feeding: A Systematic Review,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2008, 69(4):666-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/18370569/pubmed\" id=\"18370569\" target=\"_blank\">",
"        18370569",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg RJ, &ldquo;Managing Psychosis-Related Behavioral Problems in the Elderly,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1997, 12(Suppl C):4-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hendrickson RG and Morocco AP, &ldquo;Quetiapine Cross-Reactivity Among Three Tricyclic Antidepressant Immunoassays,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2003, 41(2):105-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/12733845/pubmed\" id=\"12733845\" target=\"_blank\">",
"        12733845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin A, Koenig K, Scahill L, et al, &ldquo;Open-Label Quetiapine in the Treatment of Children and Adolescents With Autistic Disorder,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1999, 9(2):99-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/10461820/pubmed\" id=\"10461820\" target=\"_blank\">",
"        10461820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McConville BJ, Arvanitis LA, Thyrum PT, et al, &ldquo;Pharmacokinetics, Tolerability, and Clinical Effectiveness of Quetiapine Fumarate: An Open-Label Trial in Adolescents With Psychotic Disorders,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2000, 61(4):252-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/10830145/pubmed\" id=\"10830145\" target=\"_blank\">",
"        10830145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneider LS, Tariot PN, Dagerman KS, et al, &ldquo;Effectiveness of Atypical Antipsychotic Drugs in Patients With Alzheimer's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(15):1525-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/17035647/pubmed\" id=\"17035647\" target=\"_blank\">",
"        17035647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw JA, Lewis JE, Pascal S, et al, &ldquo;An Open Trial of Quetiapine in Adolescents With a Diagnosis of a Psychotic Disorder&rdquo; [poster NCDEU 41st Annual Meeting, Phoenix, AZ: May 28.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widschwendter CG, Zernig G, and Hofer A, &ldquo;Quetiapine Cross Reactivity with Urine Methadone Immunoassays,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(1):172.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/17202566/pubmed\" id=\"17202566\" target=\"_blank\">",
"        17202566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/56/20361/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9570 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-8B28454533-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20361=[""].join("\n");
var outline_f19_56_20361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709379\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216270\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216298\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216274\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216286\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216275\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216276\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216277\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216247\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950138\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216234\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874967\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094101\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216250\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216294\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216306\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216296\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216253\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216238\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216291\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216242\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216266\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216243\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6831003\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216280\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850204\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216256\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216255\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216245\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216257\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216237\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216252\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9570|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/29/15830?source=related_link\">",
"      Quetiapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_56_20362="T cell negative, B cell negative, NK cell positive severe combined immunodeficiency";
var content_f19_56_20362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20362/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20362/contributors\">",
"     Morton J Cowan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20362/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/56/20362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/56/20362/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/56/20362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extreme form of severe combined immunodeficiency disease (SCID) is the T cell negative (T-), B cell negative (B-), natural killer cell positive (NK+) SCID phenotype, which accounts for 20 to 30 percent of all cases of SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Children with T-B-NK+ SCID present early in life with serious infections, failure to thrive, low to absent T and B cell numbers and function, and normal numbers and function of natural killer (NK) cells.",
"   </p>",
"   <p>",
"    Defects in at least five autosomal recessive genes in humans and one in animals, all involved in V(D)J recombination, result in this form of SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. Because some of the proteins encoded by these genes are also involved in DNA repair, defects in these pathways may also be associated with",
"    <span class=\"nowrap\">",
"     radiation/chemotherapy",
"    </span>",
"    sensitivity. Studies of these genetic mutations, both naturally occurring as well as engineered, have resulted in a better understanding of this critical step in T and B cell maturation.",
"   </p>",
"   <p>",
"    The biology, clinical manifestations, and treatment of T-B-NK+ severe combined immunodeficiency disease will be reviewed here. An overview of the different forms of SCID is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All the known causes for T-B-NK+ SCID involve defects in V(D)J recombination, which is the process by which the immune system generates a diverse repertoire of T and B cell receptors capable of recognizing a huge number of potential pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These receptors contain variable domains that represent the recognition portion of each specific receptor molecule.",
"   </p>",
"   <p>",
"    To better understand the pathogenesis of T-B-NK+ SCID, the following is a brief overview of the biology underlying V(D)J recombination. These processes are also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recombination mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coding regions of DNA for the variable domains of T and B cell receptors are formed during the early stages of T and B cell maturation; they involve site-specific rearrangement of segments of DNA called variable (V), diversity (D), and joining (J). For every specific antigen receptor, there is a V and J gene segment and sometimes a D gene segment that are randomly selected from among several hundred segments and recombined via V(D)J recombination.",
"   </p>",
"   <p>",
"    The process requires highly conserved sequences of DNA termed recombination signal sequences (RSSs) that flank all of the V, D, and J coding regions. For the process to begin, gene segments must be brought into a complex by a remodeling process of the local chromatin structure (",
"    <a class=\"graphic graphic_figure graphicRef71709 \" href=\"UTD.htm?17/22/17762\">",
"     figure 1",
"    </a>",
"    ). This is followed by the generation of precise DNA double-strand breaks (DSBs) at RSSs. These resulting signal ends are rejoined into what is termed a signal joint (SJ), while the coding ends are rejoined into a coding joint (CJ) (",
"    <a class=\"graphic graphic_figure graphicRef60698 \" href=\"UTD.htm?35/1/35870\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the past decade, knowledge of V(D)J recombination has greatly increased with the identification of several key factors in this pathway, the analysis of mutant cell lines, and the generation of mice carrying targeted deletions for each of these important factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. V(D)J recombination is initiated by the recombination activating gene complex",
"    <span class=\"nowrap\">",
"     (RAG1/2).",
"    </span>",
"    The RAG1 and RAG2 proteins recognize RSSs that flank the V, D, and J segments in developing T and B cells, termed the stable cleavage complex (SCC), which introduces DNA DSBs by a coordinated cleavage reaction.",
"   </p>",
"   <p>",
"    Targeted mutations in mice in either of the RAG genes result in the arrest of T and B cell development due to the inability to initiate V(D)J rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. T cell maturation is arrested at the double negative (CD4-CD8-) stage with no expression of TCR alpha beta, TCR gamma delta, or CD3. B cell development in the marrow is also blocked at an immature stage at the point at which immunoglobulin gene rearrangement is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/15\">",
"     15",
"    </a>",
"    ]. Homozygous animals have exceptionally small to absent thymuses and hypocellular spleens.",
"   </p>",
"   <p>",
"    The cleavage at the SCC sites leaves blunt signal ends (SE) and covalently sealed hairpin coding ends (CE). The SE can potentially be directly ligated while the CE require a processing step to open the hairpin and to add or delete nucleotides before the CE rejoining, further amplifying receptor diversity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonhomologous DNA end joining",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rejoining of both ends is accomplished by a process that is also involved in DNA double-strand break (DSB) repair. The pathway of repair of these DSBs in eukaryotic organisms is called nonhomologous DNA end joining (NHEJ). In contrast, in yeast, most of the double-stranded DNA repair that occurs uses homologous recombination, a process that involves copying the needed information from one homologous portion of DNA to another. NHEJ requires the modification of the two broken ends of DNA so that they are compatible with each other prior to rejoining.",
"   </p>",
"   <p>",
"    DNA-PKcs, Artemis, the Ku complex (Ku 86 and Ku 70), XRCC4, DNA ligase IV, and",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    are essential factors that have also been identified in mammalian NHEJ utilized by V(D)J",
"    <span class=\"nowrap\">",
"     recombination/DNA",
"    </span>",
"    repair. Studies of mutant cells and mice have demonstrated their essential roles, while also revealing their functional differences [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Although possessing certain DNA-binding and kinase activities alone, DNA-PKcs requires the involvement of Ku proteins to recruit it to DNA ends and stabilize its binding so that it is efficiently activated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     DNA-PKcs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) knockout mouse has a relatively normal phenotype with the exception of an increased sensitivity to ionizing-radiation and impaired lymphocyte development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/19\">",
"     19",
"    </a>",
"    ]. DNA-PKcs is associated with the NHEJ process of DNA repair and its deficiency would be expected to result in a more devastatingly abnormal phenotype, similar to that seen with XRCC4 or DNA ligase IV deficiencies. However, alternative protein kinase pathways exist that can compensate in the DNA repair process when DNA-PKcs is missing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ku proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ku proteins constitute the major DNA end-binding activity in nuclear extracts from mammalian cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/17\">",
"     17",
"    </a>",
"    ]. Other than recruiting and stimulating DNA-PKcs, Ku also possibly functions in stabilizing broken DNA ends and bringing them together, as well as recruiting other components (terminal deoxytransferase (TdT) and the DNA ligase",
"    <span class=\"nowrap\">",
"     IV/XRCC4",
"    </span>",
"    complex) to the DNA ends to facilitate end-joining [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/13\">",
"     13",
"    </a>",
"    ]. Impairment of lymphocyte development differs between Ku86- and Ku70-deficient mice, possibly indicating a subunit-specific Ku function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, both Ku 70 and Ku 86 deficient mice have a severe phenotype in addition to impaired coding and signal ends formation, ionizing-radiation sensitivity and lymphocyte developmental arrest, including growth retardation and signs of premature senescence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. DNA ligase IV couples with XRCC4 to execute the final ligation of SJ and CJ ends [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     XRCC4 and DNA ligase IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The targeted deletion in mice of either XRCC4 or LIG4 (the DNA ligase IV gene) exhibits a pleiotropic phenotype including late embryonic lethality, severe impaired lymphocyte development, and massive apoptosis of newly generated neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/24\">",
"     24",
"    </a>",
"    ]. The DNA ends must be ligated as part of the DNA repair process, and this is implemented by a DNA Ligase IV-XRCC4 complex. XRCC4 (X-ray-complementing Chinese hamster gene 4) has no known enzymatic activity, but functions as a scaffolding protein that helps attract other repair proteins to the DNA break. XRCC4 stabilizes LIG4 and enhances its activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/25\">",
"     25",
"    </a>",
"    ]. LIG4 is capable of ligating one DNA strand at a time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cernunnos/XLF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in the nonhomologous end-joining factor 1 gene (NHEJ1 gene) that codes for the protein Cernunnos, also named XRCC4 like factor (XLF), lead to a T-B-NK+ radiation-sensitive SCID phenotype with associated developmental delay and microcephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. T cells are absent, except for memory T cells, and patients have a progressive loss of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role(s) that the",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    protein plays in V(D)J",
"    <span class=\"nowrap\">",
"     recombination/DNA",
"    </span>",
"    repair is still being elucidated. Crystallography suggests that it is part of the",
"    <span class=\"nowrap\">",
"     XRCC4/DNA",
"    </span>",
"    ligase IV complex [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    is weakly bound to the complex and is not required for its stability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/29\">",
"     29",
"    </a>",
"    ]. It enhances the DNA ligation activity of the",
"    <span class=\"nowrap\">",
"     XRCC4/DNA",
"    </span>",
"    ligase IV complex by promoting its readenylation. This protein appears to play an essential role in gap filling that is required prior to ligation in the process of DNA DSB repair via the NHEJ pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Artemis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artemis (or DCLRE1C) is a novel protein that underlies the pathogenesis of T-B-NK+ SCID subtypes, Athabascan SCID (SCIDA) and radiation-sensitive SCID (RS-SCID). In addition to T cell maturation arrest, mutations in the ARTEMIS gene result in B cell differentiation arrest at the pre-B-cell receptor checkpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role(s) that this protein plays in the latter stage of V(D)J",
"    <span class=\"nowrap\">",
"     recombination/DNA",
"    </span>",
"    repair have not been completely delineated; however, Artemis is required for the maintenance of a normal DNA damage-induced cell cycle arrest, and the radiosensitivity and chromosomal instability seen in Artemis-deficient cells may be due to defects in cell cycle responses after DNA damage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/32\">",
"     32",
"    </a>",
"    ]. It is essential for coding joint formation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/5,33\">",
"     5,33",
"    </a>",
"    ] and is a nuclear-based protein [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/34\">",
"     34",
"    </a>",
"    ]. These defects have also been observed in mice with the targeted disruption of Artemis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Artemis is also an effective phosphorylation substrate of DNA-PKcs, and it physically interacts with DNA-PKcs to form a strong complex [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, following complex formation, Artemis acquires exonuclease activity and is able to open synthetic hairpin structures and process the 3' ends of sequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic defects and radiation sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all of the defects in the V(D)J recombination pathway result in radiation sensitivity. As an example, RAG1 or RAG2 deficient humans or mice do not exhibit abnormally increased sensitivity to radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/37\">",
"     37",
"    </a>",
"    ]. This is expected since RAG1 and RAG2 are only involved in V(D)J recombination, but not DNA repair.",
"   </p>",
"   <p>",
"    However, SCID mice with DNA-PKcs deficiency reveal increased radiation sensitivity as do fibroblasts from patients with Artemis, LIG4, and NHEJ1 abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/6,38\">",
"     6,38",
"    </a>",
"    ]. This is of clinical importance in that children with SCID who are being prepared for allogeneic related or unrelated donor bone marrow transplants are frequently treated with alkylating agents to increase the chance of engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/1,39-41\">",
"     1,39-41",
"    </a>",
"    ]. The significantly increased morbidity and mortality in the patients with T-B-NK+ phenotype who are not RAG1 or RAG2 deficient may be due to the inability to efficiently repair therapy-induced DSBs.",
"   </p>",
"   <p>",
"    A rapid test for radiation sensitivity would be ideal in the evaluation of newly diagnosed children with SCID prior to conditioning for hematopoietic cell transplantation (HCT). Unfortunately, the only screening study available requires a fibroblast cell line from the patient. Once the fibroblast cell line is generated, the test is relatively straightforward and can detect patients with possible Artemis or LIG4 defects. However, it generally takes six to eight weeks to obtain an adequate fibroblast culture. For many children with SCID, this delay in diagnosis can reduce their chances of survival.",
"   </p>",
"   <p>",
"    Thus, for children with autosomal recessive SCID and the T-B-NK+ phenotype, genotyping for RAG1, RAG2 and Artemis mutations should be done through commercial laboratories prior to any conditioning for HCT. Particular clinical features are associated with specific defects leading to radiation-sensitive SCID and can aid in the identification of children with the T-B-NK+ immunophenotype who are radiation sensitive in the absence of a rapid test. As examples, patients with LIG4 defects (DNA ligase IV deficiency) usually have other manifestations, including microcephaly and in utero and postgestation growth retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/42\">",
"     42",
"    </a>",
"    ], and patients with",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    defects also have microcephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUBGROUPS OF PATIENTS WITH T-B-NK+ SCID",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, defects in at least five autosomal recessive genes in humans and one in animals, all involved in V(D)J recombination, result in the T-B-NK+ SCID phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/3-8,10,11\">",
"     3-8,10,11",
"    </a>",
"    ]. There are two principal types of patients with T-B-NK+ SCID associated with V(D)J recombination defects, those without and with radiation sensitivity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-B-NK+ SCID without radiation sensitivity &mdash; Severe mutations in RAG1 or RAG2 genes result in T-B-NK+ SCID without radiation sensitivity. Certain RAG mutations that result in partial protein expression and limited production of T and B cells with fairly distinct clinical manifestations are known as Omenn syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Omenn syndrome is included in this type of T-B-NK+ SCID, although it is a \"leaky\" SCID with production of nonfunctioning T and B cells and therefore may appear to be T+B+NK+ SCID. Other gene defects can also cause Omenn syndrome. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Omenn syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Radiation-sensitive T-B-NK+ SCID &mdash; The other type of T-B-NK+ SCID is radiation-sensitive SCID, which includes Athabascan SCID, found in Athabascan-speaking Native Americans [",
"      <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is an estimated incidence of 1:500,000 for autosomal recessive SCID among outbred populations and 1:10,000 for first cousin marriages [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/46\">",
"     46",
"    </a>",
"    ]. By comparison, Athabascan SCID (SCIDA) is inherited as an autosomal recessive disease with an estimated incidence in the Navajo population of 1:2000 live births and an estimated gene frequency of 2.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/47\">",
"     47",
"    </a>",
"    ], which is higher than the incidence of approximately 1:3100 to 3340 live births reported previously [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     T-B-NK+ SCID without radiation sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A defect causing T-B-NK+ SCID that involves the recombination activating genes (RAG1 or RAG2) was recognized in 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/3\">",
"     3",
"    </a>",
"    ]. In this initial report, EBV-transformed lymphocytes from marrows of T-B- SCID patients had defective V(D)J rearrangements and absent expression of either RAG1 or RAG2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/3\">",
"     3",
"    </a>",
"    ]. Six of 14 patients with this severe phenotype were found to have mutations in either RAG1, RAG2, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/4\">",
"     4",
"    </a>",
"    ]. While several of these patients had detectable T cells associated with maternal engraftment, at least one had a small number of autologous oligoclonal T cells, suggesting a \"leaky\" defect in T cell maturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Omenn syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1965, Omenn described a group of children with an autosomal recessive disease that included a constellation of clinical and laboratory manifestations such as an unusual exudative skin rash, lymphadenopathy, hepatosplenomegaly, eosinophilia, and elevated levels of IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 30 years later, mutations in either RAG1 or RAG2 were found in most patients previously diagnosed with Omenn syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/37,51\">",
"     37,51",
"    </a>",
"    ]. The majority of patients have one non-functional RAG mutation and a second poorly functional mutation, resulting in a restricted T cell receptor repertoire. However, children in the same family have been found with either Omenn syndrome, a SCID-related disorder that can fall into the combined immunodeficiency (CID) category, or the classic T-B-NK+ SCID phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/52\">",
"     52",
"    </a>",
"    ]. Molecular analysis of genes in these children has revealed identical mutations resulting in one or the other phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/52\">",
"     52",
"    </a>",
"    ]. These results suggest that the theory of a \"leaky\" defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/53\">",
"     53",
"    </a>",
"    ] caused by a partially functioning RAG protein cannot completely explain the Omenn syndrome phenotype.",
"   </p>",
"   <p>",
"    It is now clear that other gene mutations, including those involving Artemis and IL-7R alpha proteins, can result in a clinical and immunologic phenotype that is indistinguishable from RAG-related Omenn syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation-sensitive SCID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for Artemis (DCLRE1C) was found to be defective in a group of patients with T-B-NK+ SCID, whose fibroblasts previously had been shown to be radiation sensitive (RS-SCID) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/38\">",
"     38",
"    </a>",
"    ]. These individuals were mostly of European descent and were previously reported to have defects in V(D)J recombination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/38\">",
"     38",
"    </a>",
"    ]. Multiple mutations in Artemis have now been identified in most patients previously diagnosed with RS-SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1979, one study reported a high incidence of SCID in Navajo and Apache Indians [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/48\">",
"     48",
"    </a>",
"    ] who are part of the Athabascan linguistic group of Native Americans who migrated to the Southwestern United States from Alaska and Canada between 700 and 1300 AD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. It is believed that the Athabascan-speaking peoples originated in Asia and crossed into North America via the Bering land mass [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/57\">",
"     57",
"    </a>",
"    ]. It was hypothesized that SCIDA was due to a founder mutation that occurred prior to the completion of the Navajo and Apache migration into the Southwestern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/58\">",
"     58",
"    </a>",
"    ]. Defective coding joint formation was found in fibroblasts from one SCIDA patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/33\">",
"     33",
"    </a>",
"    ]. While the incidence of some inherited diseases (such as cystic fibrosis) is very low in the Navajo and Apache, there is a uniquely high incidence of T-B-NK+ SCID in these Native American groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shortly after the finding linking Artemis mutations with RS-SCID on chromosome 10p [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/33,58\">",
"     33,58",
"    </a>",
"    ], a homozygous point mutation in Artemis was discovered in a large group of Navajo and Apache Indian children with T-B-NK+SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/34\">",
"     34",
"    </a>",
"    ]. The discovery of the homozygous point mutation in multiple Navajo and Apache kindreds confirmed the founder hypothesis.",
"   </p>",
"   <p>",
"    Hypomorphic mutations in genes for DNA ligase IV (LIG4) and",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    (NHEJ1) appear to result in a similar immune phenotype, although the clinical phenotype is typically less severe. Thus, these deficiencies are generally considered SCID-related disorders or combined immunodeficiencies. Affected patients often also have growth retardation, developmental delay, and microcephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/26,42\">",
"     26,42",
"    </a>",
"    ]. Fibroblasts from patients with these conditions have increased sensitivity to radiation, suggesting an associated defect in DNA repair.",
"   </p>",
"   <p>",
"    A child with T-B-NK+ SCID and radiation sensitivity was reported with a mutation in DNA-PKcs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/10,59\">",
"     10,59",
"    </a>",
"    ]. DNA-PKcs function was normal, but the mutation affected it's binding to Artemis which was inactive and resulted in the disease phenotype. Spontaneous DNA-PKcs mutations are reported in mice, Arabian horses, and Jack Russell terriers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Affected animals have the T-B-NK+ phenotype and die early in life from opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p>",
"    In general, children with T-B-NK+ SCID present early in life with serious infections typical of all children with SCID, failure to thrive, low to absent T and B cell numbers and function, and normal numbers and function of NK cells. Characteristic laboratory manifestations include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphopenia",
"      <span class=\"nowrap\">",
"       (&lt;1000/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Hypogammaglobulinemia",
"     </li>",
"     <li>",
"      Absent B cells",
"      <span class=\"nowrap\">",
"       (&lt;50/microL)",
"      </span>",
"      with absent isohemagglutinin titers (&lt;1:8) and no response to immunizations",
"     </li>",
"     <li>",
"      Absent T cells",
"      <span class=\"nowrap\">",
"       (&lt;50/microL)",
"      </span>",
"      with low to absent proliferative responses to mitogens and alloantigens (&lt;10 percent of normal)",
"     </li>",
"     <li>",
"      Normal number and function of NK cells (100 to",
"      <span class=\"nowrap\">",
"       200/microL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all affected patients display these findings. Children with the Omenn syndrome and Athabascan-speaking Navajo and Apache Indian children with SCIDA have the following clinical variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Omenn syndrome phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Omenn syndrome generally have the early onset (less than three months) of a diffuse, exudative erythroderma, lymphadenopathy, hepatosplenomegaly, chronic persistent diarrhea, and failure to thrive. These manifestations are suggestive of graft-versus-host-disease (GvHD), although skin histology is not consistent with the diagnosis and there is no evidence of maternal engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/60\">",
"     60",
"    </a>",
"    ]. These children also have elevated IgE levels and hypereosinophilia (500 to",
"    <span class=\"nowrap\">",
"     10,000/microL).",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    contrast to the more typical T-B-SCID defects, patients with Omenn syndrome have low to normal T cell numbers with oligoclonal T cells and more than 80 percent of their CD4+ cells are CD45RO+, ie, memory T cells. However, these cells lack the normal diverse T cell repertoire, being oligoclonal in nature and having poor to absent proliferation to antigens in vitro with low to no antibody responses to immunizations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The finding of activated T cells with increased production of IL-4, IL-5, and IL-10 at least in part may explain some of the clinical and laboratory manifestations of this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, defects in peripheral and central tolerance may explain some of the autoimmune features of Omenn syndrome. Regulatory T cells fail to suppress proliferation of CD4+ responder T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/62\">",
"     62",
"    </a>",
"    ]. Expression of autoimmune regulator (AIRE) protein is decreased, leading to reduced elimination of autoreactive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RAG1 and RAG2 are located in close proximity to two genes associated with aniridia, paired box gene 6 (PAX6) and Wilm tumor 1 gene (WT1) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/64\">",
"     64",
"    </a>",
"    ]. One case was reported of a child who presented with aniridia in association with the Omenn syndrome phenotype due to mutations in both RAG and PAX6 genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Athabascan phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another relatively unique clinical form of T-B-NK+ SCID is found in Athabascan speaking Native Americans with SCIDA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39,48\">",
"     39,48",
"    </a>",
"    ]. SCIDA infants present with symptoms developing within three months of age. Chronic diarrhea and failure to thrive occurs in virtually all affected infants who are not diagnosed at birth or prenatally because of a positive family history.",
"   </p>",
"   <p>",
"    An interesting and unique clinical feature of SCIDA is the presence of Noma-like ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In 18 patients with SCIDA that were followed at a single institution, 12 developed unique deep and painful ulcerative lesions of the oral mucosa or genitalia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. Extensive studies of biopsy tissue and exhaustive culturing attempts have failed to explain the etiology or pathogenesis of the lesions, although restoration of T cell immunity post BMT is associated with complete resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39,65,66\">",
"     39,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphopenia (absolute lymphocyte count =",
"    <span class=\"nowrap\">",
"     507&plusmn;315/microL)",
"    </span>",
"    is present in all SCIDA patients including those with maternal engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. In SCIDA children without maternal engraftment, the absolute number of CD3+ and CD19+ lymphocytes is very low",
"    <span class=\"nowrap\">",
"     (12&plusmn;9/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     5&plusmn;4/microL,",
"    </span>",
"    respectively). Immunoglobulin levels are also low to absent and the lymphocyte proliferative responses to mitogen and alloantigen are also low to absent, while NK numbers and function are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. SCIDA patients have an absent thymus on chest x-ray and approximately 20 percent have evidence of maternal engraftment at diagnosis, which may be associated with GvHD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. The degree to which the SCIDA and RS-SCID phenotypes are similar is unclear, although to date the skin and dental manifestations have only been reported in SCIDA.",
"   </p>",
"   <p>",
"    In addition, there is a theoretical increased risk of malignancy for those with defects that also involve DNA repair: SCIDA and RS-SCID. Mice that are deficient in both Artemis and p53 develop progenitor B cell lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/67\">",
"     67",
"    </a>",
"    ]. To date, however, an increased incidence of malignancy has not been observed in children with SCIDA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. However, four children from two kindreds have been described with mutations in the distal exon of Artemis, thereby leaving a partially functioning protein [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/68\">",
"     68",
"    </a>",
"    ]. These patients demonstrated chromosomal instability although they had polyclonal T and B lymphocyte populations. Two of these children developed EBV-associated lymphomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with T-B-NK+ SCID present with signs and symptoms typical of all children with SCID (ie, failure to thrive, chronic mucocutaneous fungal infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opportunistic infections). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .) If the child has laboratory manifestations and a lymphocyte phenotype that are characteristic, then the diagnosis of T-B-NK+ can be made, with the specific etiology still to be determined by mutational analysis.",
"   </p>",
"   <p>",
"    If the lymphocyte phenotype is not characteristic of T-B-NK+ SCID (ie, T and B cells are present but lymphocyte proliferative tests and antibody responses are low to absent), then the T cell receptor repertoire should be skewed with oligoclonal bands. Careful studies for maternal engraftment should also be done in these patients. Children with Omenn syndrome (in particular, RAG1 or RAG2 defects) characteristically do not have evidence for maternal engraftment, while those with Artemis defects can have maternal engraftment. The \"leaky\" SCID phenotype (ie, T+B+NK+) is now well-recognized in a number of the defects associated with V(D)J recombination, including RAG1, RAG2, and Artemis, as well as other SCID genes (eg, IL7R and IL2RG) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with an atypical phenotype who have eczematous rashes particularly of the scalp should also be evaluated for Omenn syndrome. Those with deep ulcerative lesions in the mouth or perianal area may have Artemis deficiency. In addition, those with growth retardation, developmental delay,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microcephaly may have DNA ligase IV or",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF",
"    </span>",
"    deficiency.",
"   </p>",
"   <p>",
"    The specific etiology for T-B-NK+ SCID can be determined by mutation analysis of the RAG1, RAG2, Artemis, LIG4, and NHEJ1 genes. DNA-PKcs is a large gene and standard mutation analysis is difficult and not readily available. However, any patient with T-B-NK+ SCID who has normal RAG1, RAG2 and",
"    <span class=\"nowrap\">",
"     Artemis/SCIDA",
"    </span>",
"    function should be evaluated for other possible defects in the V(D)J pathway, including DNA-PKcs, DNA ligase IV, and",
"    <span class=\"nowrap\">",
"     Cernunnos/XLF.",
"    </span>",
"   </p>",
"   <p>",
"    Prenatal diagnosis using either chorionic villous samples (at approximately 10 to 11 weeks gestation) or amniotic fluid fibroblasts (at 17 to 19 weeks gestation) is available for those fetuses at risk for SCID due to RAG1, RAG2, or Artemis mutations. T-B-NK+ SCID can also be diagnosed in utero by lymphocyte phenotyping of fetal blood samples.",
"   </p>",
"   <p>",
"    Children with an atypical phenotype should also be evaluated for other etiologies of SCID, including adenosine deaminase deficiency, purine nucleoside phosphorylase deficiency and interleukin-7 receptor alpha deficiency among others. Males should be evaluated for IL2RG (common gamma chain) defects. Mutations in at least 14 genes can cause SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/70\">",
"     70",
"    </a>",
"    ]. The differential diagnosis of children with this presentation also includes neonatal HIV infection and Letterer-Siwe disease (histiocytosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is the treatment of choice and the only known cure for children with T-B-NK+ SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/2,71,72\">",
"     2,71,72",
"    </a>",
"    ]. As with all SCID HCT recipients, the outcome is very good for affected children with the T-B-NK+ phenotype if an HLA matched related donor is available [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. However, survival after HLA-non-identical transplantation is worse among those with the T-B- phenotype than that observed in children with the T-B+ form when an identical HLA matched donor is unavailable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective review of the European experience with 178 T cell-depleted HLA non-identical donor transplants, the disease free survival for patients with T-B- SCID was only 35 percent at a median period of 52 months compared with 60 percent at 57 months in the T-B+ SCID group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/40\">",
"     40",
"    </a>",
"    ]. The relatively poor survival of those with T-B- SCID was associated with an increased graft failure rate and a delay in immune reconstitution post-HCT. At one year post-transplant, for example, less than 20 percent of the T-B- recipients had normal B cell immunity compared to 50 percent of the T-B+ patients. Conditioning with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    provided the best cure rate in both groups (74 and 43 percent for T-B+ and T-B- recipients, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Preconditioning regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloablative preparative regimens facilitate engraftment and immune reconstitution. However, these regimens also significantly increase transplant morbidity and mortality, especially in young infants.",
"   </p>",
"   <p>",
"    Whether or not to provide pre-HCT conditioning of any form in patients with T-B-NK+ SCID to a large degree depends upon donor availability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39,40,71,73-78\">",
"     39,40,71,73-78",
"    </a>",
"    ]. In general, conditioning therapy is not needed to achieve at least T cell reconstitution when HLA-matched donors are available. However, successful engraftment of haplocompatible T cell depleted parental grafts is significantly reduced in children with T-B-NK+ SCID compared with those with T-B+NK- SCID. This is presumed to be due to the presence of normal functioning NK cells, which are known to mediate graft resistance. Thus, conditioning should be considered for those in whom there is no maternal engraftment and an HLA-matched donor is not available. Patients with maternal engraftment are already tolerant of maternal cells. Thus, the mother can be used as the donor without conditioning in these patients, as long as the graft is T cell depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with defects in RAG1 or RAG2 are more likely to tolerate aggressive conditioning regimens than non-RAG1 or RAG2 types of T-B-NK+ SCID, because those with RAG1 or RAG2 defects are able to repair DNA damaged from myeloablative regimens. Patients with Artemis deficiency appear to be more susceptible to adverse effects from such regimens. In addition, these patients are at least theoretically at higher risk for malignancy secondary to radiotherapy due to their inability to effectively repair DNA. No increased incidence of malignancy has been seen in Artemis-deficient children to date [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. However, two children with defects in Artemis resulting in a partially functioning protein have developed EBV-associated lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best approach for preconditioning for HCT in children with the radiation and alkylating agent-sensitive types of T-B-NK+ SCID is still being evaluated. Some form of immunosuppression with an alkylating agent is generally necessary for transplantation with haplocompatible T cell depleted stem cells (unless maternal cells are present), although this preconditioning is associated with increased morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. There is limited experience with unrelated donors in this group. As an example, it is unknown whether or not a perfectly matched unrelated donor will engraft in this patient population without some immunosuppressive conditioning therapy. There are limited unpublished data that suggest this is the case in some forms of SCID, although studies are needed in this patient population.",
"   </p>",
"   <p>",
"    Addition of donor T cells to the T cell depleted graft has been performed in an attempt to provide some degree of engraftment advantage. In a murine model of in utero transplantation, the presence of donor T cells in the graft was shown to promote multilineage engraftment of mismatched grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/80\">",
"     80",
"    </a>",
"    ]. However, there was no apparent increase in engraftment in a prospective study of children with SCID who received megadose CD34+ haplocompatible stem cell transplantation in which a fixed dose of T cells was added to the graft [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/79\">",
"     79",
"    </a>",
"    ]. However, immune reconstitution in those who did engraft was comparable to that seen with HLA matched sibling grafts.",
"   </p>",
"   <p>",
"    An alternative approach may be the use of monoclonal antibodies (eg, Campath-1H or rabbit anti-thymocyte globulin), which bind to NK cells and induce apoptosis as well as suppress NK function, therefore reducing graft resistance mediated by NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Preliminary results suggest this approach may be effective, although more studies are needed.",
"   </p>",
"   <p>",
"    By comparison, some form of conditioning regimen is possible for those with RAG1 or RAG2 types of T-B-NK+ SCID who undergo HCT with haplocompatible T cell depleted related donor grafts or unrelated donor grafts, because these patients are better able to tolerate the DNA damage induced by conditioning regimens. However, late effects are associated with exposure to immunosuppressive and myeloablative agents in these young infants. Thus, alternative approaches are needed for these patients as well.",
"   </p>",
"   <p>",
"    It appears that at least some degree of myeloablative conditioning is also required to achieve B cell reconstitution in many children with SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/40,76\">",
"     40,76",
"    </a>",
"    ]. In one European study, for example, none of the T-B- SCID recipients who did not receive conditioning developed B cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/1\">",
"     1",
"    </a>",
"    ]. The failure to reconstitute B cell immunity in T-B-NK+ SCID suggests a more complex maturation process for the B cell lineage and absence of the selective advantage that appears to exist for donor T cells.",
"   </p>",
"   <p>",
"    In earlier studies, suboptimal immune reconstitution appeared to be a significant problem after haploidentical T cell depleted HCT for SCID, with patients requiring more than one transplant to achieve successful T cell immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/2,39,40\">",
"     2,39,40",
"    </a>",
"    ]. However, subsequent experience suggests that this may not be the case [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Athabascan SCID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good results with HCT are reported among children with Athabascan SCID. An overall 75 percent long term survival was observed in one study of 16 patients with Athabascan SCID, all of whom had received a related BMT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients were generally transplanted at an early age (mean 2.3 months) and had a relatively short interval between diagnosis and BMT (mean of 1.5 months). As an example, seven of the 16 infants were diagnosed either in utero or at birth (because of a positive family history) with early transplantation prior to the onset of serious infections. The use of non-myeloablative conditioning regimens in 14 of 16 initial transplants also likely contributed to the absence of mortality in the immediate post-transplantation period and subsequent long-term survival.",
"   </p>",
"   <p>",
"    However, myeloablative conditioning appears to be required for adequate B cell reconstitution in children with SCIDA. In the previous study, two of the three SCIDA patients to achieve B cell reconstitution received myeloablative conditioning regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ]. Unfortunately, only one of these children is a long-term survivor who suffers from short stature and absence of permanent tooth development. The use of an immunosuppressive conditioning regimen or no conditioning resulted in T cell, but not B cell, reconstitution in 11 of 12 initial transplants for SCIDA.",
"   </p>",
"   <p>",
"    The long-term outcome with respect to growth and development post-transplant for the majority of SCIDA patients is quite good [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ], although Artemis deficiency is a risk factor for late complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/83\">",
"     83",
"    </a>",
"    ]. Certain complications, including pulmonary alveolar hemorrhage in one patient and the absence of secondary teeth in three children (all of whom received pre-transplant chemotherapy), are unexplained and not typically seen in other forms of SCID, although this latter complication has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/84\">",
"     84",
"    </a>",
"    ]. Whether or not the dental complications in the SCIDA patients are related to their underlying genetic defect or their putative radiation sensitivity remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Omenn syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of transplants for Omenn syndrome have use intensive myeloablative and immunosuppressive conditioning, regardless of the donor-recipient match or donor source [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. This is because Omenn syndrome patients have relatively large numbers of T cells, of which some are activated and capable of cytotoxic function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the outcome with conditioning does not appear to be as good as with other forms of SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/40,71\">",
"     40,71",
"    </a>",
"    ]. In one small study of six patients with Omenn syndrome, three died of transplant-related complications within three months of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cord blood transplantation (CBT) after myeloablative conditioning or reduced intensity conditioning was successful in several case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Excellent immune reconstitution of T, B, and NK cells was seen within 12, 4, and 2 months, respectively, in a single infant who received CBT after myeloablative conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/85\">",
"     85",
"    </a>",
"    ]. Cord blood derived T cells appeared to be able to eliminate activated Omenn T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of either no conditioning or immunosuppressive conditioning alone (eg, low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) for the initial HCT in children with non-RAG1 or RAG2 types of T-B-NK+ SCID is suggested. Donor marrow 'boosts' or repeat BMT with myeloablative conditioning should be reserved for those cases in which the initial procedure results in inadequate T cell immune reconstitution or graft failure, respectively.",
"   </p>",
"   <p>",
"    No conditioning is necessary for transplantation with HLA matched related donors (and possibly with a perfectly matched unrelated donor) in order to achieve durable T cell reconstitution and, in some cases, B cell reconstitution. An HLA matched related donor may be used without conditioning therapy even with maternal engraftment. The mother should be used as the donor if maternal engraftment is present and an HLA matched relative is unavailable. Under these circumstances, thorough T cell depletion of the graft should be performed to decrease the risk of GvHD.",
"   </p>",
"   <p>",
"    Immunosuppressive conditioning is generally necessary for those children without maternal engraftment or an HLA matched relative, although in one study 43 percent of children with NK+ SCID without maternal engraftment and no conditioning engrafted with haplocompatible donors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/79\">",
"     79",
"    </a>",
"    ]. When used, the standard immunosuppressive conditioning regimen for these patients is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , with or without anti-thymocyte globulin. This regimen is reasonably well-tolerated with little apparent long-term sequelae, unless there is also an associated DNA repair defect (eg, Artemis deficiency).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    was evaluated at several centers as a replacement for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    because of its more specific T cell immunosuppressive capability and less toxic side effects. However, fludarabine has little to no effect on NK cells and preliminary results with haplocompatible grafts are discouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third approach for immunosuppressive conditioning is the use of Campath-1H, a monoclonal antibody that may suppress NK cell function sufficiently to prevent rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/81\">",
"     81",
"    </a>",
"    ]. The experience to date is insufficient to draw any definitive conclusions as to whether Campath-1H will be a more optimal approach than using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Most transplant centers have used standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimens for myeloablation when an HLA-matched related donor is not available. If a closely matched",
"    <span class=\"nowrap\">",
"     (9/10)",
"    </span>",
"    unrelated adult donor or mismatched cord blood is used, conditioning with myeloablative doses of busulfan and immunoablation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    is also effective and is less toxic than busulfan and cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/90\">",
"     90",
"    </a>",
"    ]. While the myeloablative regimens are more likely to result in B cell reconstitution, they are also associated with a higher morbidity and mortality than the immunosuppressive regimens or no conditioning approaches. This is largely due to the fact that the majority of children with SCID are ill at the time of diagnosis with opportunistic infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to thrive and are therefore more susceptible to toxic chemotherapy. With the success of newborn screening for SCID and its implementation in a growing number of states, the number of newly diagnosed patients with severe life-threatening infections will diminish significantly. However, instead of being three to six months old at the time of diagnosis and transplant, most SCID children will be newborns and potentially even more susceptible to the short and long term toxicities of alkylating agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that gene therapy was successful for children with the X-linked form of SCID (T-B+NK- phenotype) is encouraging, although the development of leukemia in several children treated is worrisome and will require further study. Since the responsible genes have been identified for at least some of the T-B-NK+ SCID types, gene transfer into hematopoietic stem cells for these disorders may be possible, at least to correct the T and B cell immunodeficient state. Gene correction using lentiviral vectors has been reported in animal models of RAG and Artemis deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. However, some caution is necessary because of the finding that over-expression of Artemis is lethal to the cell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For RAG deficient patients, including Omenn syndrome, successful gene therapy should be curative. However, there is a potential increased risk of malignancy for the defects that also involve DNA repair (eg, Artemis-deficient SCID), although an increased incidence of malignancy has not been observed to date in those children with complete Artemis deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6590970\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An extreme form of severe combined immunodeficiency disease (SCID) is the T cell negative (T-), B cell negative (B-), natural killer cell positive (NK+) SCID phenotype, which accounts for 20 to 30 percent of all cases of SCID. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All the known causes for T-B-NK+ SCID involve defects in V(D)J recombination, which is the process by which the immune system generates a diverse repertoire of T and B cell receptors capable of recognizing a huge number of potential pathogens. Defects in these pathways may also be associated with",
"      <span class=\"nowrap\">",
"       radiation/chemotherapy",
"      </span>",
"      sensitivity because some of the proteins encoded by these genes are also involved in DNA repair. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two principal types of patients with T-B-NK+ SCID associated with V(D)J recombination defects, those without and with radiation sensitivity. Severe mutations in RAG1 or RAG2 genes result in T-B-NK+ SCID without radiation sensitivity. Certain RAG mutations that result in partial protein expression and limited production of T and B cells with fairly distinct clinical manifestations are known as Omenn syndrome. Omenn syndrome is included in this type of T-B-NK+ SCID, although it is a \"leaky\" SCID with production of nonfunctioning T and B cells and therefore may appear to be T+B+NK+ SCID. The other type of T-B-NK+ SCID is radiation-sensitive SCID (RS-SCID), which includes Athabascan SCID (SCIDA), found in Athabascan-speaking Native Americans. RS-SCID is primarily due to Artemis mutations. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Subgroups of patients with T-B-NK+ SCID'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with T-B-NK+ SCID present early in life with serious infections and failure to thrive. Several unique features are seen in children with Omenn syndrome and Athabascan-speaking Navajo and Apache Indian children with SCIDA. Children with Omenn syndrome generally have early onset (less than three months) of diffuse, exudative erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic persistent diarrhea. They also have elevated IgE levels and hypereosinophilia. A unique clinical feature of SCIDA is the presence in about 60 percent of patient of Noma-like ulcers, deep and painful ulcerative lesions of the oral mucosa or genitalia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical and laboratory manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristic laboratory manifestations include lymphopenia, hypogammaglobulinemia, absent B cells with absent isohemagglutinin titers and no response to immunizations, absent T cells with low to absent proliferative responses to mitogens and alloantigens, and normal number and function of NK cells. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical and laboratory manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of T-B-NK+ can be made in a child who presents with signs and symptoms typical of SCID (ie, failure to thrive, chronic mucocutaneous fungal infections,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opportunistic infections) and the characteristic lymphocyte phenotype and laboratory manifestations. The T cell receptor repertoire should be skewed with oligoclonal bands and studies for maternal engraftment should always be performed whether or not the lymphocyte phenotype is characteristic of T-B-NK+ SCID (ie, T and B cells are present but lymphocyte proliferative tests and antibody responses are low to absent). The specific etiology is determined by mutational analysis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation (HCT) is the treatment of choice and the only known cure for children with T-B-NK+ SCID. The outcome is very good for affected children with the T-B-NK+ phenotype if an HLA-matched related donor is available. However, survival after HLA-non-identical transplantation is worse among those with the T-B- phenotype than that observed in children with the T-B+ form when an identical HLA-matched donor is unavailable. Improved outcomes with HLA-matched unrelated adult donors and mismatched cord blood units have been reported, and it is possible that conditioning may not be necessary with a perfectly matched unrelated donor. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"       \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/1\">",
"      Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998; 91:3646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/2\">",
"      Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993; 123:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/3\">",
"      Abe T, Tsuge I, Kamachi Y, et al. Evidence for defects in V(D)J rearrangements in patients with severe combined immunodeficiency. J Immunol 1994; 152:5504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/4\">",
"      Schwarz K, Gauss GH, Ludwig L, et al. RAG mutations in human B cell-negative SCID. Science 1996; 274:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/5\">",
"      Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001; 105:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/6\">",
"      Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A 1996; 93:10285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/7\">",
"      Wiler R, Leber R, Moore BB, et al. Equine severe combined immunodeficiency: a defect in V(D)J recombination and DNA-dependent protein kinase activity. Proc Natl Acad Sci U S A 1995; 92:11485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/8\">",
"      Meek K, Kienker L, Dallas C, et al. SCID in Jack Russell terriers: a new animal model of DNA-PKcs deficiency. J Immunol 2001; 167:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/9\">",
"      de Villartay JP. V(D)J recombination and DNA repair: lessons from human immune deficiencies and other animal models. Curr Opin Allergy Clin Immunol 2002; 2:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/10\">",
"      van der Burg M, Ijspeert H, Verkaik NS, et al. A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest 2009; 119:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/11\">",
"      Enders A, Fisch P, Schwarz K, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J Immunol 2006; 176:5060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/12\">",
"      Fugmann SD, Lee AI, Shockett PE, et al. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 2000; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/13\">",
"      Grawunder U, Harfst E. How to make ends meet in V(D)J recombination. Curr Opin Immunol 2001; 13:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/14\">",
"      Lieber MR. The biochemistry and biological significance of nonhomologous DNA end joining: an essential repair process in multicellular eukaryotes. Genes Cells 1999; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/15\">",
"      Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/16\">",
"      Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/17\">",
"      Gu Y, Sekiguchi J, Gao Y, et al. Defective embryonic neurogenesis in Ku-deficient but not DNA-dependent protein kinase catalytic subunit-deficient mice. Proc Natl Acad Sci U S A 2000; 97:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/18\">",
"      Gao Y, Sun Y, Frank KM, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998; 95:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/19\">",
"      Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991; 9:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/20\">",
"      Barnes DE, Stamp G, Rosewell I, et al. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol 1998; 8:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/21\">",
"      Zhu C, Bogue MA, Lim DS, et al. Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell 1996; 86:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/22\">",
"      Gu Y, Seidl KJ, Rathbun GA, et al. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity 1997; 7:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/23\">",
"      Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol 1997; 7:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/24\">",
"      Frank KM, Sharpless NE, Gao Y, et al. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 2000; 5:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/25\">",
"      Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009; 417:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/26\">",
"      Buck D, Malivert L, de Chasseval R, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006; 124:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/27\">",
"      Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006; 124:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/28\">",
"      Li Y, Chirgadze DY, Bolanos-Garcia VM, et al. Crystal structure of human XLF/Cernunnos reveals unexpected differences from XRCC4 with implications for NHEJ. EMBO J 2008; 27:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/29\">",
"      Riballo E, Woodbine L, Stiff T, et al. XLF-Cernunnos promotes DNA ligase IV-XRCC4 re-adenylation following ligation. Nucleic Acids Res 2009; 37:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/30\">",
"      Akopiants K, Zhou RZ, Mohapatra S, et al. Requirement for XLF/Cernunnos in alignment-based gap filling by DNA polymerases lambda and mu for nonhomologous end joining in human whole-cell extracts. Nucleic Acids Res 2009; 37:4055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/31\">",
"      Noordzij JG, Verkaik NS, van der Burg M, et al. Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. Blood 2003; 101:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/32\">",
"      Zhang X, Succi J, Feng Z, et al. Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol 2004; 24:9207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/33\">",
"      Moshous D, Li L, Chasseval R, et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum Mol Genet 2000; 9:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/34\">",
"      Li L, Moshous D, Zhou Y, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002; 168:6323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/35\">",
"      Li L, Salido E, Zhou Y, et al. Targeted disruption of the Artemis murine counterpart results in SCID and defective V(D)J recombination that is partially corrected with bone marrow transplantation. J Immunol 2005; 174:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/36\">",
"      Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002; 108:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/37\">",
"      Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001; 97:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/38\">",
"      Nicolas N, Moshous D, Cavazzana-Calvo M, et al. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 1998; 188:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/39\">",
"      O'Marcaigh AS, DeSantes K, Hu D, et al. Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans. Bone Marrow Transplant 2001; 27:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/40\">",
"      Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency. J Pediatr 1999; 134:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/41\">",
"      Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/42\">",
"      van der Burg M, van Veelen LR, Verkaik NS, et al. A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest 2006; 116:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/43\">",
"      Niehues T, Perez-Becker R, Schuetz C. More than just SCID--the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2. Clin Immunol 2010; 135:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/44\">",
"      Asai E, Wada T, Sakakibara Y, et al. Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol 2011; 138:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/45\">",
"      Nahas SA, Gatti RA. DNA double strand break repair defects, primary immunodeficiency disorders, and 'radiosensitivity'. Curr Opin Allergy Clin Immunol 2009; 9:510.",
"     </a>",
"    </li>",
"    <li>",
"     Gatti RA, O'Reilly RJ. Severe combined immunodeficiency. In: Birth defects compendium, Bergsma D (Ed), Sinayer Associates, Sunderland, MA 1979. p.575.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/47\">",
"      Jones JF, Ritenbaugh CK, Spence MA, Hayward A. Severe combined immunodeficiency among the Navajo. I. Characterization of phenotypes, epidemiology, and population genetics. Hum Biol 1991; 63:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/48\">",
"      Murphy S, Hayward A, Troup G, et al. Gene enrichment in an American Indian population: an excess of severe combined immunodeficiency disease. Lancet 1980; 2:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/49\">",
"      OMENN GS. FAMILIAL RETICULOENDOTHELIOSIS WITH EOSINOPHILIA. N Engl J Med 1965; 273:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/50\">",
"      Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008; 122:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/51\">",
"      Santagata S, Villa A, Sobacchi C, et al. The genetic and biochemical basis of Omenn syndrome. Immunol Rev 2000; 178:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/52\">",
"      Corneo B, Moshous D, G&uuml;ng&ouml;r T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood 2001; 97:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/53\">",
"      Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 2008; 122:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/54\">",
"      Grunebaum E, Bates A, Roifman CM. Omenn syndrome is associated with mutations in DNA ligase IV. J Allergy Clin Immunol 2008; 122:1219.",
"     </a>",
"    </li>",
"    <li>",
"     Krauss ME. Native languages of the Americas, Sebeok TA (Ed), Plenum Press, New York 1979. p.150.",
"    </li>",
"    <li>",
"     Kehoe AB. North American Indians: A comprehensive account, Prentice-Hall, 1981. p.449.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/57\">",
"      Renfrew C. World linguistic diversity. Sci Am 1994; 270:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/58\">",
"      Li L, Drayna D, Hu D, et al. The gene for severe combined immunodeficiency disease in Athabascan-speaking Native Americans is located on chromosome 10p. Am J Hum Genet 1998; 62:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/59\">",
"      van der Burg M, van Dongen JJ, van Gent DC. DNA-PKcs deficiency in human: long predicted, finally found. Curr Opin Allergy Clin Immunol 2009; 9:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/60\">",
"      Appleton AL, Curtis A, Wilkes J, Cant AJ. Differentiation of materno-fetal GVHD from Omenn's syndrome in pre-BMT patients with severe combined immunodeficiency. Bone Marrow Transplant 1994; 14:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/61\">",
"      de Saint-Basile G, Le Deist F, de Villartay JP, et al. Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest 1991; 87:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/62\">",
"      Cassani B, Poliani PL, Moratto D, et al. Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol 2010; 125:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/63\">",
"      Somech R, Simon AJ, Lev A, et al. Reduced central tolerance in Omenn syndrome leads to immature self-reactive oligoclonal T cells. J Allergy Clin Immunol 2009; 124:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/64\">",
"      Sheehan WJ, Delmonte OM, Miller DT, et al. Novel presentation of Omenn syndrome in association with aniridia. J Allergy Clin Immunol 2009; 123:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/65\">",
"      Rotbart HA, Levin MJ, Jones JF, et al. Noma in children with severe combined immunodeficiency. J Pediatr 1986; 109:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/66\">",
"      Kwong PC, O'Marcaigh AS, Howard R, et al. Oral and genital ulceration: a unique presentation of immunodeficiency in Athabascan-speaking American Indian children with severe combined immunodeficiency. Arch Dermatol 1999; 135:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/67\">",
"      Rooney S, Sekiguchi J, Whitlow S, et al. Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc Natl Acad Sci U S A 2004; 101:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/68\">",
"      Moshous D, Pannetier C, Chasseval Rd Rd, et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 2003; 111:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/69\">",
"      Pasic S, Djuricic S, Ristic G, Slavkovic B. Recombinase-activating gene 1 immunodeficiency: different immunological phenotypes in three siblings. Acta Paediatr 2009; 98:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/70\">",
"      Griffith LM, Cowan MJ, Kohn DB, et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008; 122:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/71\">",
"      Loechelt BJ, Shapiro RS, Jyonouchi H, Filipovich AH. Mismatched bone marrow transplantation for Omenn syndrome: a variant of severe combined immunodeficiency. Bone Marrow Transplant 1995; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/72\">",
"      Di Martino D, Terranova MP, Valetto A, et al. An unusual pattern of B-cell immunological reconstitution after allogeneic stem cell transplantation: a possible correlation with CMV reactivation? Pediatr Transplant 2009; 13:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/73\">",
"      Gomez L, Le Deist F, Blanche S, et al. Treatment of Omenn syndrome by bone marrow transplantation. J Pediatr 1995; 127:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/74\">",
"      Junker AK, Chan KW, Massing BG. Clinical and immune recovery from Omenn syndrome after bone marrow transplantation. J Pediatr 1989; 114:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/75\">",
"      Lanfranchi A, Verardi R, Tettoni K, et al. Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency. Haematologica 2000; 85:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/76\">",
"      Friedrich W, M&uuml;ller SM. Allogeneic stem cell transplantation for treatment of immunodeficiency. Springer Semin Immunopathol 2004; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/77\">",
"      Friedrich W, H&ouml;nig M. HLA-haploidentical donor transplantation in severe combined immunodeficiency. Immunol Allergy Clin North Am 2010; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/78\">",
"      M&uuml;ller SM, Kohn T, Schulz AS, et al. Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood 2000; 96:4344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/79\">",
"      Dvorak CC, Hung GY, Horn B, et al. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant 2008; 14:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/80\">",
"      Bhattacharyya S, Chawla A, Smith K, et al. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice. J Immunol 2002; 169:6133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/81\">",
"      Condiotti R, Nagler A. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity. Bone Marrow Transplant 1996; 18:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/82\">",
"      Stauch D, Dernier A, Sarmiento Marchese E, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 2009; 4:e4709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/83\">",
"      Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009; 113:4114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/84\">",
"      Cole BO, Welbury RR, Bond E, Abinun M. Dental manifestations in severe combined immunodeficiency following bone marrow transplantation. Bone Marrow Transplant 2000; 25:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/85\">",
"      Sch&ouml;nberger S, Ott H, Gudowius S, et al. Saving the red baby: successful allogeneic cord blood transplantation in Omenn syndrome. Clin Immunol 2009; 130:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/86\">",
"      Benito A, Diaz MA, Alonso F, et al. Successful unrelated umbilical cord blood transplantation in a child with Omenn's syndrome. Pediatr Hematol Oncol 1999; 16:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/87\">",
"      Tomizawa D, Aoki Y, Nagasawa M, et al. Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. Eur J Haematol 2005; 75:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/88\">",
"      Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 2005; 35:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/89\">",
"      D&iacute;az de Heredia C, Ortega JJ, D&iacute;az MA, et al. Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. Bone Marrow Transplant 2008; 41:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/90\">",
"      Veys P. Reduced intensity transplantation for primary immunodeficiency disorders. Pediatr Rep 2011; 3 Suppl 2:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/91\">",
"      Mostoslavsky G, Fabian AJ, Rooney S, et al. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A 2006; 103:16406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/56/20362/abstract/92\">",
"      Lagresle-Peyrou C, Yates F, Malassis-S&eacute;ris M, et al. Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity. Blood 2006; 107:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3950 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20362=[""].join("\n");
var outline_f19_56_20362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6590970\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recombination mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonhomologous DNA end joining",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - DNA-PKcs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ku proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - XRCC4 and DNA ligase IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cernunnos/XLF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Artemis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic defects and radiation sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUBGROUPS OF PATIENTS WITH T-B-NK+ SCID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      T-B-NK+ SCID without radiation sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Omenn syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation-sensitive SCID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL AND LABORATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Omenn syndrome phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Athabascan phenotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Preconditioning regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Athabascan SCID",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Omenn syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6590970\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3950|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/22/17762\" title=\"figure 1\">",
"      Recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/1/35870\" title=\"figure 2\">",
"      Post cleavage complex",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_56_20363="Hepatocellular causes jaundice";
var content_f19_56_20363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hepatocellular conditions that can produce jaundice",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Viral hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatitis A, B, C, D, and E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Epstein-Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Predictable, dose-dependent (eg, acetaminophen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unpredictable, idiosyncratic (many drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Environmental toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vinyl chloride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Jamaica bush tea - pyrrolizidine alkaloids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wild mushrooms - Amanita phalloides or verna",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilson disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20363=[""].join("\n");
var outline_f19_56_20363=null;
var title_f19_56_20364="Initial assessment cocaine";
var content_f19_56_20364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial assessment of the cocaine-abusing patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       I. Patient history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       a. Use of all psychoactive substances (not just cocaine), including illegal, prescription, and over-the-counter as well as duration, quantity, frequency, route of administration, and effects for each substance used",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       b. Prior treatment, if any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       c. Psychiatry history, including relationship of any psychiatric symptoms to substance use or withdrawal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       d. Medical history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       e. Social and developmental history, especially current social network",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       II. Family history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       a. Substance use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       b. Psychiatric history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       III. Mental status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       a. Insight into condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       b. Motivation and preferences for treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       c. Cognitive function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Orientation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Attention span",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Memory, short- and long-term",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Decision-making capacity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       d. Presence of thought disorder, eg, delusions, hallucinations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       e. Mood and affect",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       IV. Physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       a. Vital signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       b. Heart, lungs, abdomen, extremities, skin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       c. Neurological examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       V. Laboratory tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       a. Blood or urine drug testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       b. Electrocardiogram",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       c. Complete blood count (CBC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       d. Blood chemistries, including liver tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       e. Blood-borne and sexually transmitted diseases, eg, HIV, syphilis, hepatitis B and C",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rawson, RA (ed). Treatment for Stimulant Use Disorders (TIPS #33). Center for Substance Abuse Treatment, Rockville, MD 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20364=[""].join("\n");
var outline_f19_56_20364=null;
var title_f19_56_20365="Human TCR gamma chain";
var content_f19_56_20365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Organization of the human T cell receptor gamma chain locus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 134px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are six functional V gamma genes, five pseudogenes (red boxes), and three unused genes with ORFs (boxes with Xs). There are three J gamma 1, and two J gamma 2 gene segments. There is one each of C gamma 1 and C gamma 2.",
"    <div class=\"footnotes\">",
"     ORFs: open reading frames.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Leiden, JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20365=[""].join("\n");
var outline_f19_56_20365=null;
var title_f19_56_20366="Prevalence obesity children";
var content_f19_56_20366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 660px\">",
"   <div class=\"ttl\">",
"    Prevalence of obesity* among children and teenagers, by age group and selected period--United States, 1963-2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 640px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Children with body mass index (BMI) values at or above the 95th percentile of&nbsp;the sex-specific body mass index (BMI) growth charts released by the Centers for Disease Control (CDC) in&nbsp;2000.",
"    </div>",
"    <div class=\"reference\">",
"     National Health and Nutrition Examination Surveys. Additional information is available at:",
"     <a href=\"file://www.cdc.gov/nchs/fastats/overwt.htm\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/nchs/fastats/overwt.htm",
"     </a>",
"     .",
"     <br/>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20366=[""].join("\n");
var outline_f19_56_20366=null;
var title_f19_56_20367="Post bronchocscopic laser resection";
var content_f19_56_20367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/80129/postlase_conv.mp4?title=Post+bronchocscopic+laser+resection\" style=\"width:240px;height:196px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoscopic laser resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopy shows restablishment of a patent airway following bronchoscopic laser resection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_56_20367=[""].join("\n");
var outline_f19_56_20367=null;
